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Alzheimer’s disease (AD) is the most common type of dementia for the elderly 
and is the sixth-leading cause of death in the U. S.. The complete mechanism of 
AD still remains unclear and currently there is no effective disease-modifying 
drug to delay or cure this disease. Although aberrant Wnt inhibition has been 
implicated in AD pathogenesis, the role of Wnt co-receptors low density 
lipoprotein receptor-related protein (LRP) 5 and LRP6 has yet to be established. 
Thus, the overall goal of this study is to explore the functional role of LRP5 and 
LRP6 in AD. Herein we explored two different objectives: 
(1) To assess the protective role of LRP5 and LRP6 against hydrogen peroxide-
induced neurotoxicity and tau phosphorylation. 
(2) To investigate the effect of LRP5 and LRP6 on apolipoprotein (apo) E4-
induced abnormalities in mitochondrial dynamics. 
 
In the first part, we showed that the overexpression of LRP5 and LRP6 activated 
Wnt signaling in SH-SY5Y cells which was evidenced by elevated T-cell specific 
transcription factor/lymphoid enhancer factor 1 (TCF/LEF) reporter activities and 
increased β-catenin protein levels.  The transcription of downstream survival 
xv 
 
genes Axin2 and Cyclin D1 is consequently increased. On the other hand, 
knockdown of LRP5 and LRP6 in SH-SY5Y cells resulted in a decrease in 
Wnt/β-catenin activity and a reduction in survival gene expression. We further 
demonstrated that overexpression of LRP5 and LRP6 protected SH-SY5Y cells 
from cell death caused by hydrogen peroxide-induced oxidative stress. In addition, 
this overexpression significantly suppressed the activity of GSK3β and resulted in 
the reduction of tau phosphorylation. In the second part, we established the direct 
interaction between apoE isoforms and LRP5/6. We observed that the interaction 
between apoE isoforms and LRP5 disrupted the activation ability of LRP5 and 
exerted isoform-specific effects on GSK3β activity. Furthermore, we 
demonstrated the detrimental effect of apoE4 in causing mitochondrial dynamics 
disruption with the aberrantly increased expression of mitochondrial fission 
proteins, dynamin-related protein 1 (Drp1) and mitochondrial fission 1 (Fis1), and 
decreased expression of mitochondrial fusion protein mitofusin (Mfn) 2. 
Subsequently, the changes in mitochondrial morphology towards fission were 
observed. In addition, we identified dickkopf (DKK) 1 as the inhibitor to disrupt 
the interaction between apoE4 and LRP5/6. Subsequent disruption of apoE4 and 
LRP5/6 interaction by DKK1 resulted in a reduction of the elevated mitochondrial 
fission proteins and an increase of the repressed mitochondrial fusion protein, 
followed by the restoration of normal mitochondrial dynamics. In conclusion, our 
data not only indicated the functional role of LRP5 and LRP6 in AD, but also 
xvi 
 
provided a better understanding in the mechanisms underlying apoE4-induced AD 
pathology. With further characterization and studies, LRP5 and LRP6 may 
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CHAPTER 1. INTRODUCTION 
 
1.1  Alzheimer’s disease and current therapeutic approaches 
Alzheimer’s disease (AD) is a progressive age-associated neurodegenerative 
disorder and is the most common type of dementia among the elderly. It was first 
discovered by a German psychiatrist named Alois Alzheimer in 1906 [1] and 
manifests as a progressive decline in memory and cognitive functions followed by 
changes in behavior. AD is pathologically characterized by senile plaques formed 
by abnormal assemblies of β-amyloid (Aβ) and neurofibrillary tangles (NFTs) 
composed of hyperphosphorylated forms of microtubule-associated tau protein, as 
well as the loss of neurons and synaptic connections [2-5]. In the U.S. alone, it 
was estimated that 5.2 million people suffered from AD in 2013, out of which 
approximately 200,000 people are younger than 65 years while the other 5 million 
makes up the late-onset AD population. [6]. The AD population is projected to 
affect 13.8 million people in the U.S. by 2050 [6]. 
 
Despite intensive scientific research, there are currently no effective 
pharmacotherapeutic options that can slow down or stop AD progression. To date, 
only symptomatic treatment aimed at counterbalancing the disturbance in 
neurotransmitter levels is available for the treatment of AD. These drugs are 
designed based on the cholinergic hypothesis which states that changes in the 
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cholinergic system such as loss of acetylcholine neurons, reduced choline uptake 
and acetylcholine release are responsible for the deterioration in cognitive 
functions observed in AD [7-9]. Thus, cholinesterase inhibitors, blocking the 
degradation of acetylcholine between the synapses, are developed and used as the 
standard first-line treatment for AD. These drugs mainly include donepezil, 
rivastigmine and galantamine, approved for the treatment of mild to moderate AD 
[10]. Another agent currently approved for the treatment of moderate to severe 
AD is memantine [11], an N-methyl-D-aspartate receptor antagonist. Memantine 
selectively blocks abnormal transmission of the excitotoxic neurotransmitter, 
glutamate, that was released at high levels in transgenic mice as well as AD 
patients [12].   
 
Despite the effectiveness in treating behavioral symptoms, the major drawback of 
these symptomatic agents is the lack of improvement in cognitive functions in AD 
patients.  Thus, novel treatment approaches or ‘disease-modifying’ drugs, aimed 
at reversing the pathogenic steps in AD have been under extensive development 
[13,14].  Based on the amyloid hypothesis that overproduction and aggregation of 
Aβ is the main driver of AD pathogenesis, a large group of disease-modifying 
drugs has been developed to counteract the increase in Aβ production and plaque 
deposition. However, results from human clinical trials with these amyloid-
targeting drugs have largely been disappointing (Table 1-1). A second group of 




Table 1-1. Disease-modifying treatments targeting Aβ.  
Drug name Mechanism Results Phases Ref. 
Tramiprosate Interfere with the binding of glycosaminoglycanes 
and Aβ, resulting in inhibiting Aβ aggregation 
(-) The overall changes in psychometric scores and 
hippocampus volume were not significant  
III [15] 
Colostrinin Inhibit Aβ aggregation and neurotoxicity (±) The beneficial effects on cognition function 
(p=0.02) and daily activities (p=0.03) were moderate. 
II [16] 
Scyllo-inositol Stabilize oligomeric aggregates of Aβ and inhibit 
Aβ toxicity 
(-) The changes in neuropsychological test and daily 
activities were not significant. 
II [17] 





oligomerization of Aβ 
(±) The improvement in ADAS-cog score was near-
significant. 
IIa [18] 




Tarenflurbil Inhibit γ-secretase (-) No improvement was observed in ADAS-cog score 
and ADCS-ADL scale. 
III [20] 
Avagacestat Inhibit γ-secretase Ongoing II [21] 





Table 1-1. Disease-modifying treatments targeting Aβ. (continued) 
Drug name Mechanism Results Phases Ref. 





Human Aβ residues (4-10) to initiate active 
immunization 
Ongoing II [24] 
Bapineuzumab Aβ N-terminal directed, humanized monoclonal 
antibody 
(-) No improvement in ADAS-cog and DAD scores 
was shown. 
III [25] 
Solanezumab Aβ central domain directed, humanized 
monoclonal antibody 
(-) Solanezumab failed to improve cognition or 
functional ability. 
III [24] 
IVIg Natural anti-amyloid antibodies found in human 
intravenous immunoglobulins 
(-) No significant differences in cognitive and 
functional abilities were observed.  
III [26] 
 
Results for clinical trials: +, encouraging results; -, disappointing results; ±, doubtful results. 
Abbreviations: ADAS-cog, AD Assessment Scale-cognitive; ADCS-ADL, AD Cooperative Studies–activities of daily living; DAD, 
Disability Assessment for Dementia. 
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developed and is currently in early stages of clinical trials or pre-clinical trials. 
These agents mainly include methylene blue for interfering with tau deposition 
[27], lithium for disrupting tau phosphorylation [28] and tau targeting vaccines 
[13]. Treatments targeting a number of other pathogenic mechanisms have also 
been considered, including inflammation [29], oxidative stress [30], iron 
deregulation [31] and cholesterol metabolism [32]. Despite promising premises 
associated with different pathogenic pathways, phase III clinical trials of many 
potentially disease-modifying drugs failed to demonstrate any improvement on 
cognition. Hence, the mechanisms of AD pathogenesis still need to be thoroughly 
understood and investigated before large efforts are put into drug development 
and clinical trials.  
 
1.2  AD classification 
1.2.1  Early-onset AD 
The pathogenesis of AD involves an interplay of complex interactions between 
multiple genetic and environmental factors. Early-onset AD (EOAD) or familial 
AD develops before the age of 65 and only accounts for less than 1% of AD 
population [33,34]. The primary cause for EOAD has been attributed to the 
overproduction and aggregation of Aβ, owing to mutations in either the amyloid 
precursor protein (APP) gene or presenilin (PSEN) 1 or 2 genes which are the 
essential components in the γ-secretase complex. Figure 1-1 shows the 
amyloidogenic and non-amyloidogenic processing of APP by three different 
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enzymes, α-, β- and γ-secretases [3,35]. α- secretase cleaves APP within Aβ 
sequence and generate soluble APP fragment α (sAPPα) and C-terminal fragment 
83 (C83). C83 is further cleaved by γ-secretase into non-amyloidogenic peptide 
p3 [36]. In this non-amyloidogenic pathway, the production of Aβ is precluded 
and none of these products are toxic. On the other hand, in the amyloidogenic 
pathway, β-secretase cleavage of APP creates soluble APP fragment β (sAPPβ) 
and C-terminal fragment 99 (C99), the latter of which is subsequently processed 
by γ-secretase to release Aβ. Genetic mutations in APP and PSEN1&2 accelerate 
the generation of Aβ which was proposed as the prime pathogenic driver for AD 
by the amyloid hypothesis [37]. Elevation and aggregation of Aβ subsequently 
leads to tau phosphorylation, cell death and other histological features in AD. 
 
Figure 1-1. Amyloidogenic and non-amyloidogenic processing of APP. sAPPα, 
soluble APP fragment α; sAPPβ, soluble APP fragmentβ; AICD, amyloid precursor 
protein intracellular domain. The image was taken from Ref [38].  
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1.2.2  Late-onset AD 
Over 99% of AD cases occur late in life (>65 years) and are referred as late-onset 
AD (LOAD). Genome-wide association studies (GWAS) have shown that the ε4 
allele of the apolipoprotein E (APOE4) gene is the main genetic risk factor for 
LOAD [33,34,39]. Human APOE gene exists as three polymorphic alleles ε2, ε3, 
and ε4 which have a frequency of 8.4%, 77.9% and 13.7% respectively in the 
general population, but a frequency of 3.9%, 59.4% and 36.7% respectively in the 
AD population (Figure 1-2) [40]. Aging is the most important known non-genetic 
risk factor for LOAD. Other potential environmental risk factors include brain 
trauma, diabetes mellitus, hypertension, obesity, smoking, depression, cognitive 
inactivity or low educational attainment, and physical inactivity [41-44].  
 
 
Figure 1-2. The structure of apoE and the meta-analysis on the populations of 




1.3  Apolipoprotein E4 
1.3.1  Structure and function 
The human apoE protein is a 299-amino acid glycoprotein with a molecular 
weight of 34 kDa [46,47]. ApoE is synthesized by various organs with the highest 
expression in liver and central nervous system (CNS). In brain cells, apoE is 
primarily expressed by astrocytes and microglia [48,49]. Neurons are also able to 
express apoE in response to pathological stimulation such as excitotoxic injury 
[50,51]. The human APOE gene has multiple single nucleotide polymorphisms 
(SNPs) across the whole gene [52]. The three most common SNPs result in 
common isoforms of apoE with different amino acid residues in 112 and 158, 
where either cysteine (Cys) or arginine (Arg) is present: apoE2 (Cys112, Cys158), 
apoE3 (Cys112, Arg158), and apoE4 (Arg112, Arg158) [53]. ApoE has two 
structural domains: a 22-kDa N-terminal domain (residues 1-191) containing the 
low-density lipoprotein (LDL) receptor binding region (residues 136-150), a 10-
kDa C-terminal domain (residues 216-299) containing the lipid binding region 
(residues 244-272) and a hinge region to join the two domains (Figure 1-2) 
[45,47]. Cys158 in apoE2 disrupts the receptor binding ability in N-terminal 
domain [54], while Arg158 in apoE4 mediates N-terminal and C-terminal domain 





ApoE plays important roles in regulating lipid homeostasis via lipid transportation 
among cells in CNS [46,57,58]. ApoE-containing lipoproteins redistribute lipids 
such as cholesterol to repair the injured neurons. However, apoE4 does not seem 
to be as efficient as apoE3 in protecting neurons. Expression of apoE3, not apoE4, 
protects against excitotoxin-induced neuronal damage in mice and age-dependent 
neurodegeneration in APOE
-/-
 mice [59]. ApoE3 and 4 also have opposite effects 
on neurite extension with apoE3 stimulating and apoE4 inhibiting neurite 
outgrowth [60-62]. Blocking apoE3 by specific antibody completely abolishes the 
neurite-promoting effect [62]. 
 
1.3.2  ApoE4 neuropathology in AD 
1.3.2.1  Effect of apoE4 on Aβ production and clearance 
Studies with transgenic mice and humans indicated that apoE4 induces Aβ 
accumulation and deposition in the brain [63-66]. Although the underlying 
molecular basis is still largely unknown, in vitro and in vivo studies suggested that 
apoE isoforms may have differential effects on Aβ production as well as soluble 
Aβ clearance. In rat neuroblastoma B103 cells overexpressed with human wild-
type APP, apoE4 increased Aβ production to a greater extent than apoE3 (60% vs 
30%) [67]. In addition to the effect on stimulating Aβ production, apoE4 disrupts 
the clearance of soluble Aβ in the brain. Sadowski et al. reported a reduced Aβ 
pathology by antagonizing the apoE/Aβ interaction [68], suggesting this process 
may be mediated by the interaction between apoE and Aβ. Indeed, Castellano et 
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al. demonstrated that greater binding affinity of apoE2 and apoE3 to Aβ 
corresponded to greater Aβ clearance in mice [65]. Studies with microglial cells 
indicated that the endolytic degradation of Aβ was dramatically enhanced by 
apoE3 rather than apoE4 [69].  Moreover, apoE4 potentiated Aβ-induced 
lysosomal leakage and apoptosis, leading to neuronal degeneration [70]. 
 
1.3.2.2  Effect of apoE4 on tau phosphorylation 
Other than inducing pathological effects through Aβ, apoE4 also contributes to 
AD by inducing tau hyperphosphorylation and aggregation. Increased tau 
phosphorylation was observed in neurons expressing apoE4 [71-74]. Unlike 
apoE3, recombinant apoE4 did not interact with tau to form a bimolecular 
complex in vitro. Binding assays showed that apoE3 bound to the microtubule-
binding repeat region of unphosphorylated tau, suggesting the interaction may 
inhibit tau self-assembly into higher helical structure [75]. Thus, apoE4 may not 
be as efficient as apoE3 in inhibiting tau aggregation.                 
 
1.3.2.3  Effect of apoE4 on mitochondrial dysfunction 
Mitochondrial dysfunction has been described as one of the pathological 
hallmarks of AD and has been reported to be exacerbated by apoE4 presence [76-
78]. In an early study, apoE was shown to interact with mitochondrial F1-ATPase 
with high affinity [79], suggesting that apoE might play a role in mediating 
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mitochondrial function. More recently, study with Neuro-2a cells indicated that 
truncated apoE fragment translocated to mitochondria and caused mitochondrial 
dysfunction via an unknown mechanism that was mediated by the lipid binding 
region on apoE [80].  Nakamura et al. later reported that apoE fragment bound to 
UQCRC2 and cytochrome c, which are the components of mitochondrial 
respiratory complex III, and COX IV 1, the component of complex IV [81]. The 
steady-levels of mitochondrial respiratory complexes have been shown to be 
significantly lower in apoE4-expressing neurons compared with apoE3-
expressing neurons, but this effect was not observed in astrocytes, indicating a 
neuron-specific effect [82]. Subsequently, the reduced enzymatic activity of 
mitochondrial complex IV from mouse primary neurons indicated that apoE4 
lowered mitochondrial respiratory capacity [82]. Similar pattern was also 
observed in mitochondria isolated from peripheral tissues of AD patients [83].  
 
In addition to its effects on mitochondrial respiratory capacity, apoE4 has been 
reported to dysregulate other mitochondrial functions. Proteomic analysis showed 
that mitochondria isolated from hippocampal tissues in apoE3 and apoE4 
transgenic mice presented differential protein levels of several molecules that are 
involved in the processes of energy production, metabolism, oxidative stress and 
organelle transportation [84]. Post-mortem brain tissue analysis identified 30 
transcripts of differential expression proteins related to mitochondrial oxidative 
function in apoE ε4 carriers compared to non-carriers [85]. Consistent with this 
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observation, in vitro studies with B12 cells revealed that apoE isoforms possessed 
different antioxidant abilities in a manner correlated with AD risk (E2> E3> E4) 
[86]. It is possible that the beneficial or detrimental effects of different apoE 
isoforms are carried out through regulating the levels of reactive oxygen species 
(ROS), of which mitochondria is the major endogenous source [87]. In addition, 
low rates of glucose metabolism have been repeatedly associated with apoE4 in 
both normal and AD subjects [88-91]. Taken together, dysregulated mitochondrial 
function plays an important role in apoE4-induced AD pathogenesis. Other than 
disrupted mitochondrial functions, perturbance in mitochondrial dynamics has 
also been implicated in AD [78,92,93]. 
 
1.3.3  Mitochondrial dynamics  
Mitochondria are highly dynamic organelles that constantly move and undergo 
structural transitions. Moving along cytoskeletal tracks, individual mitochondria 
encounter each other and undergo fusion with the merging of double membranes. 
Conversely, an individual mitochondrion can divide by fission process to yield 
two or more shorter mitochondria. In addition to controlling mitochondrial shape 
and distribution, these two processes also facilitate the mixing of outer 
membranes, inner membranes and matrix contents to maintain genetic and 
biochemical uniformity within mitochondrial population. Balanced mitochondrial 
dynamics play a protective role in mitochondria with fission facilitating 
mitophagy of defective mitochondria and fusion contributing to retention of 
13 
 
critical material [94]. Mixing of mitochondrial proteins and DNA contents by 
mitochondrial fusion process is also critical in maintaining mitochondrial DNA 
(mtDNA) stability and mitochondrial respiratory function. Loss of mitochondrial 
fusion reduces mtDNA dramatically and causes severe mitochondrial dysfunction 
and compensatory mitochondrial proliferation [95]. Several cell lines including 
mouse embryonic fibroblasts [96], cerebellar Purkinje cells [97], skeletal 
myocytes [95], and cardiac myocytes [98] lacking mitochondrial fusion proteins 
mitofusins (Mfns) displayed declined respiratory capacity. Moreover, 
mitochondrial fission has been implicated in the process of apoptosis. Inhibiting 
mitochondrial fission protein dynamin-related protein 1 (Drp1) activity by 
knockdown approach or overexpressing a dominant-negative mutant of Drp1, 
delayed the release of apoptotic effector cytochrome c [99-101]. Apoptosis is also 
alleviated when mitochondrial fission factor (Mff) or mitochondrial fission 1 
(Fis1) is reduced [102,103]. Disturbance in mitochondrial dynamics have been 
implicated in many diseases with AD being one of them [104,105]. 
 
1.3.4  Disrupted mitochondrial dynamics in AD  
Multiple lines of evidence support that mitochondrial fusion and fission processes 
are perturbed in AD. Morphometric analysis revealed that mitochondria in AD 
neurons not only decreased in number but also enlarge in size [78]. The finding of 
enlarged and swollen mitochondria was also reported in AD cybrid cells [92] and 
fibroblasts from LOAD patients [106]. The elongated mitochondria in LOAD 
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fibroblasts were found to accumulate in perinuclear area with significantly 
decreased level of Drp1. Overexpression of wild-type Drp1 in these fibroblasts 
rescued mitochondrial abnormalities [106]. A more detailed immunoblot analysis 
indicated that the levels of Drp1, optic atrophy 1 (OPA1), Mfn 1 and 2 were 
significantly decreased whereas the level of Fis1 was increased in AD brain. 
Contrary to the above reported studies, Manczak et al. showed an increased 
expression of Drp1 and a reduction in those of Mfn1 and Mfn2 in AD patients 
[107]. Despite several studies indicating altered mitochondrial dynamics to be 
involved in AD pathogenesis, the upstream drivers of this pathological effect have 
yet to be established. Moreover, the role and mechanism of apoE4 in altering 
these mitochondrial dynamics remains unknown. It is likely that apoE4 carries out 
the detrimental effects through its receptors. Among all the apoE4 receptors, 
LRP5 and LRP6 are of particular interest due to their essential role in Wnt 
signaling, dysregulation of which has been reported to be associated with AD. 
Given the lack of information between the involvement of LRP5/6 in apoE4-
induced pathology in AD, we have attempted to address this gap in Chapter 4 and 
5. 
 
1.4  ApoE receptors 
1.4.1  Low density lipoprotein receptor family 
The strong implication of apoE4 in AD pathogenesis raised the possibility that 
apoE4 might mediate its detrimental effects at least in part through its receptors. 
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ApoE receptors include the core members from LDL receptor family such as low 
density lipoprotein (LDL) receptor-related protein (LRP) 1, apoE receptor 2 
(apoER2) as well as several more distantly related members like sorting protein-
related receptor/lipoprotein receptor 11 (SorLA/LR11), LRP5 and LRP6 
[108,109]. LDL receptor family members are a group of single transmembrane 
proteins located on the cell surface that recognizes and mediates endocytosis of 
several structurally diverse ligands. All receptors share several similar structural 
domains: Ligand-binding repeats, epidermal growth factor (EGF) precursor 
homology domains sensitive to pH, six-bladed β-propeller structure involved in 
pH dependent release of cargo, a transmembrane domain and a cytoplasmic tail 
with NPxY motifs (Figure 1-3) [110]. Most of the members are built from a 
unifying module of N-terminal Ligand-binding repeats followed by a C-terminal 
cluster of β-propeller structures. In the distantly related members, this module is 
inverted (LRP5 and LRP6) or combined with motifs that are not seen in the other 
receptors (SorLA/LR11) (Figure 1-3). Compared to the other members of this 
receptor family, LRP5 and LRP6 have been relatively less explored in AD 




Figure 1-3. The structure of LDL receptor family members. The image was taken 
from Ref [111]. 
 
1.4.2  Low density lipoprotein-related protein 5 and 6 
LRP5 and LRP6 are type I single transmembrane proteins with 1615 and 1613 
amino acid residues respectively. They share 73% and 64% identity in 
extracellular and intracellular domains. The function of LRP5 and LRP6 were 
revealed with genetic studies of depletion and overexpression. Mice lacking LRP6 
exhibited developmental defects that were similar to mutations of individual Wnt 
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genes [112]. In vitro co-immunoprecipitation assay and in vivo Xenopus embryo 
studies showed that LRP6 activated Wnt-Frizzled (Fz) signaling and induced Wnt 
responsive genes, whereas a dominant negative variant of LRP6 blocks signaling 
by Wnt or Wnt-Fz [113]. Later, Kelly et al. reported the similar reception role of 
LRP5 in Wnt signaling using mice with mutations in LRP5 [114]. Thus, LRP5 
and LRP6 are the essential co-receptors to facilitate the transduction of Wnt 
signaling. 
 
Wnt signaling is an autocrine and paracrine signaling pathway that has been 
implicated in many development processes including axis formation and midbrain 
development [115,116]. Wnt signaling pathway participates in the development of 
central nervous system and regulates the function of adult nervous system 
[117,118].  Aberrant regulated Wnt signaling has been associated with many 
diseases, including neurodegenerative disorders such as AD [119,120]. 
 
Among all the downstream pathways, only the canonical Wnt/β-catenin signaling 
pathway requires the action of LRP5 and LRP6. In the absence of Wnt ligands, a 
destruction complex composed of Axin, adenomatous polyposis coli (APC), 
glycogen synthase kinase (GSK) 3β and casein kinase 1 (CK1), phosphorylates 
the key regulator of this pathway, β-catenin [121]. Phosphorylated β-catenin is 
recognized and degraded by ubiquitin-proteasome system. Upon Wnt ligands 
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recognizing its receptor Fz on the cell surface, a complex is formed consisting of 
Wnt ligands, receptor Fz and co-receptor LRP5/6, leading to the association with 
CK1 [113,122]. This activates and recruits dishevelled (Dvl) to the cell plasma 
compartment. The activated Dvl displaces GSK3β from the destruction complex 
by recruiting GSK3 binding proteins (GBP)/Frat-1. Wnt stimulation inhibits the 
activity of GSK3β, resulting in the accumulation and nuclear translocation of β-
catenin [123]. Inside the nucleus, β-catenin binds to T-cell specific transcription 
factor/lymphoid enhancer-binding factor 1 (TCF/LEF) by replacing histone 
deacetylase (HDAC) and transcriptional corepressor Groucho and activates the 
transcription of its target genes including C-MYC, CYCLIN D1, AXIN2 that 





Figure 1-4. Schematic representation of the canonical Wnt/ β-catenin signaling 
pathway.  This image was modified from Ref [125]. 
 
Although LRP5 and LRP6 are highly homologous proteins [126-128], they may 
not carry out equivalent functions. LRP6
-/-
 mice were lethal and displayed 
mid/hindbrain defects which are the hallmarks for Wnt1-deficient mice. These 
mice revealed an excess of neural tissue and a corresponding loss of paraxial 
mesoderm, resembling to Wnt3a mutant mice. Mice depleted of LRP6 also had 
both anteroposterior and dorsoventral patterning defects, which were similar to 
mice carrying mutations in Wnt7a [112]. LRP5
-/-
 mice, however, underwent 
normal embryogenesis and could grow into adulthood. These mice displayed 
osteoporosis-pseudoglioma [129] and abnormal cholesterol metabolism [130]. 
Thus, defects in LRP6
-/-
 mice were much more severe than those in LRP5 
deficient mice, though some functional redundancy was shown in both of the 
knockout mice. Mice with LRP5; LRP6 double homozygous mutants failed to 
establish a primitive streak which resembled Wnt3 mutant mice and died earlier 
than LRP6
-/-
 single knockout mice [114]. Taken together, LRP5 and LRP6 are 
involved in transducing the signaling by different Wnt ligands. Wnt3 relies on 
either LRP5 or LRP6 to exert the function, while Wnt1, Wnt3a and Wnt7a require 
primarily LRP6 rather than LRP5. The comparison among an allelic series of 
LRP5; LRP6 knockout mice on the severity of developmental abnormalities 
indicated that LRP5 and LRP6 share overlapping function but LRP6 has a 




1.4.3  Dysregulated Wnt signaling in AD  
Numerous studies have shown that Wnt/β-catenin signaling is dysregulated at 
different levels in AD [119,131-133]. The familial AD-linked PSEN1 variant 
directly bound to β-catenin protein and formed multiprotein complexes, which 
resulted in reduced β-catenin accumulation and nuclear translocation [134-136]. 
LOAD risk factor apoE4 inhibited Wnt/β-catenin signaling and decreased β-
catenin level [137]. Activated GSK3β, with a concomitant decrease in β-catenin 
levels, has been found in AD brains with NFT [138]. In vivo studies demonstrated 
that GSK3β transgenic mice displayed the sign of neurodegeneration and spatial 
learning deficits [139]. Recently, a genome-wide linkage study identified that the 
polymorphism of LRP6 is associated with LOAD [140]. Further molecular studies 
showed that this polymorphism Ile - 1062 → Val reduced Wnt/β-catenin activity 
in HEK293T cells. Subsequently, the splice variant LRP6Δ3 (LRP6 isoform 
skipping exon 3) was also reported to be associated with AD [141].  
 
On the other hand, restoration of the repressed Wnt activity has been shown to 
have promising therapeutic effects in AD [142]. For example, activation of Wnt 
signaling by introducing Wnt ligands, Wnt3a or Wnt7a, overcame Aβ 
neurotoxicity in rat hippocampal neurons [143,144]. Similarly, lithium, the non-
specific inhibitor of GSK3β, has been widely used in activating Wnt signaling to 
rescue neurodegeneration and improve behavioral impairments in rats injected 
with preformed Aβ fibrils [145]. Another possible approach of activating Wnt 
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signaling is to introduce or overexpress functional LRP5 and LRP6, however, not 
much work has been done in this regard. It is thus one of our aims in this thesis to 
evaluate the neuroprotective role of LRP5 and LRP6 against AD pathology and it 
has been discussed in Chapter 3.  
 
1.5  Summary and concluding remarks 
Due to the numerous failures of the current AD therapies in clinical trials, there is 
a need to better understand the underlying pathological mechanisms and to 
develop novel therapeutic drug targets. Despite acting as Wnt co-receptors and 
apoE4 receptors, the functional role of LRP5 and LRP6 in AD, however, still 
remains unclear. Thus, further knowledge of LRP5 and LRP6 will not only 
provide us with deeper understanding of AD pathology, but also help us in 


























CHAPTER 2. HYPOTHESIS AND AIMS 
 
A growing body of evidence has implicated the involvement of dysregulated Wnt 
signaling in the etiology of AD. Multiple Wnt components have been reported to 
be aberrantly modulated in AD. The recent studies of LOAD have pointed out the 
contribution of genetic variations of Wnt co-receptor LRP6 in the repressed Wnt 
activity. The functional role of Wnt co-receptors LRP5 and LRP6 in AD, however, 
still remains unclear. Thus, the overall goal of this study is to characterize the role 
of LRP5 and LRP6 in AD, with the objective of better understanding of the 
underlying mechanism and identifying novel Wnt-targeted therapies to prevent or 
delay AD development and progression. 
 
In the first part of this thesis, we hypothesized that overexpression of LRP5 and 
LRP6 protects neuronal cells from cytotoxicity induced by hydrogen peroxide and 
reduces tau phosphorylation. Our hypothesis was based on several observations: 
First, LRP5 and LRP6 are the upstream co-receptors of Wnt signaling which 
plays an important role in regulating and maintaining the function of adult 
nervous system [117,118]. Second, activation of Wnt signaling either by Wnt 
ligands or GSK3β inhibitor has been shown to rescue neurodegeneration and 
improve behavioral impairment [143-145]. In addition, GSK3β has been 
implicated as one of the main tau phosphorylation kinases in the AD etiology 
[146,147]. As the direct modulators of GSK3β activity, LRP5 and LRP6 are 
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expected to affect the phosphorylation process of tau. Given these observations, 
overexpression of LRP5 and LRP6 is an attractive approach for improving 
neuronal cell survival and reducing tau phosphorylation.   
To test our first hypothesis, we explored three specific aims: 
(1) Establish the essential role of LRP5 and LRP6 in regulating Wnt/β-catenin 
activity and the expression of downstream proliferation genes.  
(2) Assess the role of LRP5 and LRP6 in improving neuronal survival and 
protecting cells from oxidative stress.  
(3) Characterize the role of LRP5 and LRP6 in reducing tau phosphorylation.  
 
Other than functioning as Wnt co-receptors, LRP5 and LRP6 also structurally 
belong to LDL receptor family. Several members from LDL receptors have been 
shown to interact with apoE isoforms [111]. However, there is no direct evidence 
of the interaction between LRP5/6 and apoE. In addition, apoE4 has been reported 
to carry out its detrimental effect through dysregulating mitochondrial function 
[81,82]. As mitochondrial function is reflected and maintained by balanced 
mitochondrial dynamics, we were interested in assessing the effect of apoE4 on 
mitochondrial dynamics and whether this process was mediated by LRP5/6. Thus, 
in the second half of this thesis, we hypothesized that apoE4 disrupts normal 
mitochondrial dynamics through binding to LRP5/6.  
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To test this second hypothesis, we had three specific aims: 
(1) Identify the interaction between Wnt co-receptors LRP5/6 and apoE 
isoforms.  
(2) Evaluate the effect of apoE4 on mitochondrial dynamics in neuronal cell 
lines.  
(3) Characterize the effect of the interaction between LRP5/6 and apoE4 on 
mitochondrial dynamics.  
Work done to address three specific aims of the first hypothesis is included in 
Chapter 3, where we showed the neuroprotective role of Wnt co-receptors LRP5 
and LRP6 against hydrogen peroxide-induced neurotoxicity and tau 
phosphorylation in SH-SY5Y neuroblastoma cells. The three aims of the second 
hypothesis are discussed in Chapter 4 and 5. In Chapter 4, we identify the 
interaction between LRP5/6 and all three common apoE isoforms and its isoform-
specific effects on GSK3β activity. In Chapter 5, we report that apoE4 disrupts 
the normal mitochondrial dynamics and this abnormal disturbance is mediated 
through binding to LRP5/6.  
 
Achieving the above aims not only provided us with deeper insights into the 
contributory role of LRP5/6 in AD, but also a new robust linkage between Wnt 
signaling and apoE4 pathology. This knowledge is useful for the subsequent 






















CHAPTER 3. PROTECTIVE ROLE OF WNT SIGNALING CO-
RECEPTORS LRP5/6 AGAINST HYDROGEN PEROXIDE-INDUCED 




Among the factors associated to the pathogenesis of AD, growing amount of 
research suggests a vital role of dysregulated Wnt activity in the etiology of AD 
[133,134,137]. Multiple Wnt components have been reported to be altered in AD 
[119,131,132]. Central to these events is the GSK3β enzyme which plays an 
upstream role in the regulation of Wnt signaling activity, as well as a downstream 
mediator of tau phosphorylation as one of the major kinases. Failing to inhibit 
GSK3β activity leads to increased tau phosphorylation in primary culture of 
hippocampal neurons [147,148]. In addition to its role in tau pathology, the 
involvement of GSK3β in AD associated oxidative stress has also been widely 
studied.  Abnormally activated GSK3β would reduce effectiveness of cellular 
defense systems, resulting in increased vulnerability to oxidative stress and 
eventually neuronal cell death [143,144]. Despite the important role of GSK3β in 
the pathogenesis of AD, currently there is no effective and safe therapeutic 




LRP 5 and LRP6 are the membrane-bound Wnt co-receptors, which modulate 
Wnt signaling pathway through directly regulating the activity of GSK3β 
[149,150]. Upon binding to Wnt ligand, LRP5 and LRP6 inhibit the 
phosphorylation activity of GSK3β by recruiting Axin to plasma membrane and 
subsequently facilitate the accumulation of β-catenin and transcription of 
downstream target genes [149,151]. Research by De Ferrari et al. has suggested a 
link between LRP6 polymorphisms and LOAD through attenuating Wnt signaling 
[140] and a more recent publication reported that a novel LRP6 gene alternative 
splice variant in AD patients diminished Wnt signaling transduction [152]. 
However, the functional in vitro studies for understanding the role of LRP5/6 in 
AD pathology are still missing in cultured neuronal cell lines. 
 
In this study, we evaluated the role of LRP5 and LRP6 in protecting neuronal 
cells against oxidative stress-induced cell death and reducing tau phosphorylation 
through regulating Wnt signaling. Our results show that overexpression of LRP5 
and LRP6 in human neuroblastoma SH-SY5Y cells activated Wnt signaling and 
upregulated downstream proliferation genes. In contrast, silencing of LRP5 and 
LRP6 resulted in the repression of Wnt activity and expression of proliferative 
markers. Furthermore, we found that increasing protein expression of LRP5 and 
LRP6 overcame the cytotoxicity increased by oxidative stress and rescued SH-
SY5Y from cell death. In addition, overexpressing LRP5 and LRP6 
phosphorylated GSK3β at Serine (Ser) 9 residue and inhibited its activity, leading 
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to reduced tau phosphorylation. These data suggest that modulation of Wnt 
activity via the co-receptors LRP5 and LRP6 may serve as an attractive 
therapeutic strategy to enhance neuronal survival in neurodegenerative diseases 
such as AD. 
 
3.2  Materials and Methods 
3.2.1  Cell culture and reagents 
All cell culture reagents were purchased from Sigma Chemical Co. (St. Louis, 
MO). Human neuroblastoma SH-SY5Y cells were cultured in Dulbecco’s 
modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS), 
100μg/mL streptomycin and 100units/mL of penicillin in a humidified chamber at 
37°C, 5% CO2. These cells were transfected with either vector alone (pcDNA3.1 
or pCS2+) or plasmids expressing the full length LRP5 (a kind gift from Dr 
Georges Rawadi, Galapagos, France) or LRP6 (a kind gift from Dr. Xi He, 
Children’s Hospital Boston, USA). Gene knockdown experiments were 
performed using double stranded short interfering RNA (siRNA) targeting LRP5 
and LRP6 purchased from Dharmacon (Lafayette, CO): LRP5 On-Target Plus 
SmartPool siRNA, LRP6 On-Target Plus SmartPool siRNA and scrambled On-
Target Plus non-targeting pool siRNA. TOPglow and pRL-CMV Renilla plasmids 
were purchased from Millipore (Bedford, MA). All transfection experiments were 
performed with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in OptiMEM 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol.  For the 
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collection of control L-cell conditioned medium and Wnt3a-conditioned medium 
(designated as LCM and WCM), both L-cells and L-cells stably transfected with a 
Wnt-3a expression factor (L-Wnt-3a cells) were kindly provided by Professor 
Victor Nurcombe (Institute of Medical Biology, A*STAR, Singapore) and 
maintained in DMEM supplemented with 10% FBS, 100μg/mL streptomycin, 
100units/mL of penicillin and 400μg/mL of G418. WCM was prepared from Wnt-
3a secreting L-Wnt-3a cells according to ATCC instructions. 
 
3.2.2  Quantitative Real-Time PCR 
Total RNA from SH-SY5Y cells was isolated using RNeasy Mini Kit (Qiagen, 
Valencia, CA), followed by on-column DNase treatment to remove genomic 
DNA contamination according to the manufacturer’s instructions. RNA samples 
were reverse-transcribed into cDNA using Superscript III 1
st
 strand Synthesis 
System Kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instruction. Quantitative Real-Time PCR was performed with iQ SYBR Green 
Supermix (Bio-Rad Laboratories, Hercules, CA) on an iCycler iQ
TM
5 Real-Time 
PCR detection system (Bio-Rad Laboratories, Hercules, CA). Relative change in 
gene expression was calculated using ΔΔCt method by iQTM5 Optical System 
software using GAPDH as an endogenous mRNA control. Primers used were as 




Table 3-1 Primers used to determine the mRNA levels of GAPDH, Cyclin D1 
and Axin2. 
Primer Name Sequence 
GAPDH forward 5'-ATG TTC GTC ATG GGT GTG AA-3'   
GAPDH reverse 5'- TGT GGT CAT GAG TCC TTC CA-3' 
Cyclin D1 forward 5'-TGT TCG TGG CCT CTA AGA TGA AG-3' 
Cyclin D1 reverse 5'-AGG TTC CAC TTG AGC TTG TTC AC-3' 
Axin2 forward 5'-ACA ACA GCA TTG TCT CCA AGC AGC-3' 
Axin2 reverse 5'-GCG CCT GGT CAA ACA TGA TGG AAT-3' 
 
3.2.3  Dual luciferase reporter assay 
SH-SY5Y cells (2.5x10
5
) were seeded in 24-well plates overnight and transfected 
with 1μg LRP5 or LRP6 expression plasmids, 1μg reporter construct (TOPglow) 
and 0.04μg pRL-CMV Renilla control plasmids. For gene knockdown assays, 
20nM siRNA was added in place of LRP5 or LRP6 expression plasmids. 
TOPglow plasmid contains four copies of the TCF binding site which is activated 
by β-catenin, whereas pRL-CMV Renilla is used for normalizing the cell count. 
After 6 hours of transfection, the medium was replaced with either LCM or WCM. 
Cells were harvested and lysed using 100μL 1 × reporter lysis buffer (Promega, 
Madison, WI) twenty-four hours post transfection and 20μL sample was 
transferred into Nunc-Immuno MicroWell 96 well polystyrene plate (Roskilde, 
Denmark). Luciferase activity was measured with the Dual-Luciferase Reporter 
Assay Kit (Promega, Madison, WI) according to the manufacturer’s instruction, 
using 100μL Dual-Glo® luciferase assay reagent to measure the firefly luciferase 
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activity and 100μL Dual-Glo® Stop&Glo® reagent to determine the Renilla 
luminescence with a luminometer (Tecan, MTX Lab Systems Inc., Vienna, VA). 
All the readings were performed in triplicates and expressed as mean ± S.E.M. of 
the normalized ratios of Firefly to Renilla luciferase and as the percentage of 
samples transfected with respective vectors. 
 
3.2.4  Western blotting analysis 
Western blotting was used to analyze the protein levels of LRP5, LRP6, β-catenin, 
dephosphorylated β-catenin, cleaved caspase 3 and 7, GSK3β and phosphorylated 
tau. Cells transfected as above mentioned were washed with phosphate buffer 
saline (PBS) and solubilized in lysis buffer (25mM Tris, 2.5mM EDTA, 2.5mM 
EGTA, 100mM NaCl, 20mM  C3H7Na2O6P, 20mM NaF, 1mM Na3VO4, 10mM 
Na4P2O7, 0.5% deoxycholate, 1% Triton X-100, pH7.4) supplemented with 
protease inhibitor cocktail tablet (Roche Diagnostics, Germany). Samples (30μg 
protein per lane) were run on 8-15% polyacrylamide SDS gels and transferred 
onto polyvinylidene fluoride membranes (Bio-Rad Laboratories, Hercules, CA). 
Non-specific binding was blocked with 5% fat-free milk in TBST (Tris Buffer 
Saline with 0.1% Tween 20) at room temperature for 1 hour. Membranes were 
incubated with primary antibodies at 4˚C overnight, washed and incubated with 
secondary antibodies at room temperature for 1 hour, followed by washing for 
another 3 times. The protein bands were visualized with the ECL Western 
Blotting detection kit (Thermo Scientific, South Logan, UT). The primary 
antibodies used were: LRP5 (Invitrogen, Carlsbad, CA), LRP6 (Cell Signaling 
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Technology, Beverly, MA), β-catenin (Santa Cruz Biotechnology, Santa Cruz, 
CA), dephosphorylated β-catenin (Millipore, Bedford, MA), GSK3β (Cell 
Signaling Technology, Beverly, MA), PHF-Tau AT8 (Thermo Scientific, South 
Logan, UT), β-actin (Santa Cruz Biotechnology, Santa Cruz, CA), cleaved 
caspase 3 (Cell Signaling, Beverly, MA), and cleaved caspase 7 (Cell Signaling, 
Beverly, MA). Anti-mouse and anti-rabbit IgG secondary antibody conjugated 
with horseradish peroxidase were purchased from GE Healthcare Life Sciences, 
US. Several Western blotting results were quantified using ImageJ 1.47 (National 
Institutes of Health, Bethesda, MD). 
 
3.2.5  Aβ25-35 and Aβ42 oligomer and fibril preparation 
Aβ25-35 was purchased from Sigma Chemical Co. (St. Louis, MO) and Aβ42 
was purchased from AnaSpec Inc. (Fremont, CA). 1,1,1,3,3,3-Hexafluoro-2-
Propanol (HFIP, Sigma Chemical Co., St. Louis, MO) was added to Aβ peptide 
with the final peptide concentration of 1mM in the bottom of the vial through the 
rubber spetum with a 1mL syringe and a sharp needle. Aβ-HFIP solution was 
sonicated for 5 min before incubation at room temperature for one hour. The 
solution was then aliquoted as 10μL in 0.2mL sterile microcentrifuge tubes. The 
tubes were open and HFIP was allowed to evaporate overnight in the fume hood. 
A thin clear film was formed at the bottom of the tubes indicating good peptide 
quality. Dried peptide films were stored in -20˚C for further use. Upon using, 
DMSO was added into peptide films and vortexed to make 5mM Aβ stock. To 
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prepare Aβ oligomers, 5mM Aβ in DMSO was diluted with ice-cold phenol-free 
and serum-free F-12 cell culture media (Sigma Chemical Co., St. Louis, MO) to a 
final concentration of 100μM Aβ. The tube was vortexed for 15 sec and aged at 
4˚C for indicated days. To prepare Aβ fibrils, 5mM Aβ in DMSO was diluted 
with ice-cold phenol-free and serum-free F-12 cell culture media (Sigma 
Chemical Co., St. Louis, MO) to a final concentration of 100μM Aβ. The tube 
was vortexed for 15 sec and aged at 37˚C for indicated days. 
 
3.2.6  Cell viability analysis 
SH-SY5Y cells were transfected with 10μg LRP5 or LRP6 plasmids in 10cm petri 
dish. For Aβ treatment, transfected cells were trypsinized and seeded with 
densities indicated in the result chapter in phenol-free FBS-free F12 medium. 
Cells were treated with a series of concentrations of Aβ25-35 and Aβ1-42 
monomers, oligomers and fibrils for 24 hours, 48 hours and 72 hours. Cell 
viability was measured using Cell Counting Kit-8 solution (CCK-8, Dojindo 
Laboratories, Kumamoto, Japan) and CytoTox 96
®
 Non-Radioactive Cytotoxicity 
Assay (Promega, Madison, WI). 10μL CCK-8 solution was added to each well of 
the 96-well plate and the plates were incubated in the CO2 incubator for 4 hours. 
The absorbance of the formazan product was measured at 450nm using 
microplate reader (Tecan Infinite® 200 PRO, Männedorf, Switzerland).  CytoTox 
96
®
 Non-Radioactive Cytotoxicity Assay was performed according to 
manufacturer’s protocol. Briefly, 20μL Lysis Solution was added to target cell 
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maximum lactate dehydrogenase (LDH) release control. After 45 min, 50μL of 
the supernatant from each well of the assay plate was transferred to the 
corresponding well of a Nunc-Immuno MicroWell 96 well polystyrene plate 
(Roskilde, Denmark). 50μL of reconstitute Substrate Mix was added to each well 
and incubated at room temperature for 30 min, protected from light. 50μL of Stop 
Solution was added and absorbance was recorded at 490nm with microplate 
reader. For hydrogen peroxide treatment, transfected cells were trypsinized and 
seeded at a density of 1.5x10
4
 cells/well for 24h before being treated with 0-50μM 
hydrogen peroxide in WCM for 24 h. Cell viability was measured using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. MTT was 
dissolved in PBS to give a concentration of 5mg/mL. 20μL of MTT solution was 
then added into each well to yield a final volume of 220μL/well. Plates were 
incubated in the CO2 incubator for 4 hours. Media were replaced with 100μL 
DMSO to dissolve formazan crystals with 20 min shaking on the orbital shaker. 
The absorbance of the formazan product was measured at 595nm using 
microplate reader.  All the experiment was repeated three times and cell viability 
was represented as the percentage of the vehicle control. 
 
3.2.7  Cell cycle analysis 
SH-SY5Y cells were transfected and treated as described in Section 3.2.5 of this 
chapter. The effect of LRP5 and LRP6 overexpression on the cell cycle 
distribution was accessed by flow cytometry after staining the cells with 
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propidium iodide (PI). Transfected cells were fixed in 100μL of PBS and 400μL 
ice-cold 70% ethanol and stored in -20˚C overnight. On the following day, 
samples were washed with PBS once and stained in 500μL PBS with 16μL/mL PI 
and 240μL/mL RNase. Cell fluorescence was measured using the Dako 
Cytomation Cyan LX (Beckman Coulter, Brea, CA) and cell cycle analysis was 
performed with Summit 4.3 software (Beckman Coulter, Brea, CA). 
 
3.2.8  Statistical analysis 
All data was presented as an average of three independent experiments ± S.E.M. 
Statistical analysis was performed using Student’s t test (SPSS, Chicago, IL) and 
significance was assumed at p < 0.05. 
 
3.3 Results 
3.3.1 LRP5 and LRP6 overexpression upregulates Wnt/β-catenin signaling 
and downstream proliferative genes in SH-SY5Y cells 
To explore the functional role of Wnt co-receptors LRP5 and LRP6 in human 
neuroblastoma SH-SY5Y cells, we first overexpressed the co-receptors in SH-
SY5Y cells and examined their effects on downstream Wnt signal transduction. 
As shown in Figure 3-1A, total and active (dephosphorylated) β-catenin protein 
levels were found to be elevated in LRP5- and LRP6-overexpressing SH-SY5Y 
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cells compared to control cells transfected with empty vectors, both in the absence 
and presence of Wnt3a ligands. In addition, we analyzed TCF/LEF transcriptional 
activities in the transfected cells using a TCF/LEF-responsive luciferase reporter 
vector (TOPglow) and found that the luciferase activities were significantly 
increased (Figure 3-1B).  Compared to the vector control, TCF/LEF 
transcriptional activities were increased by approximately 10.7- and 76.6- fold in 
the presence of Wnt3a-conditioned media in LRP5 and LRP6 transfectants 
respectively. We next examined the expression of several Wnt downstream target 
genes involved in cell proliferation such as Axin2 and Cyclin D1 and observed a 
significant increase in gene expression with LRP5 and LRP6 overexpression. As 
shown in Figure 3-1C, the mRNA levels of Axin2 and Cyclin D1 were 
significantly increased by 39.4 ± 6.8% and 25.6 ± 1.0% respectively with LRP5 
overexpression and 37.3 ± 6.2% and 40.2 ± 13.0% respectively with LRP6 
overexpression in SH-SY5Y cells treated with Wnt3a ligands. These findings 
demonstrate that LRP5 and LRP6 overexpression are effective in transducing 








































































































































































Figure 3-1. LRP5 and LRP6 overexpression upregulates Wnt/β-catenin signaling 
and downstream proliferative genes in SH-SY5Y cells. (A) SH-SY5Y cells were 
transfected with pcDNA3.1-LRP5 or pCS2+-LRP6 plasmids, followed by treatment of 
either LCM or WCM for 24 hours before harvested. Samples were solubilized with 
Western blotting lysis buffer and probed with specific antibodies, addressing the protein 
levels of LRP5/6, total β-catenin, active β-catenin, and β-actin. (B) SH-SY5Y cells were 
transfected with LRP5 or LRP6 expression plasmids together with TOPglow and pRL-
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CMV Renilla plasmids and treated with LCM or WCM for 24 hours. Wnt3a-induced 
luciferase activities were measured with Dual–Luciferase Reporter Assay Kit. Values 
represented the average (n=3) ± S.E.M. of fold activation over control vectors 
(pcDNA3.1 or pCS2+) treated with LCM. (C) LRP5 and LRP6 overexpressed SH-SY5Y 
cells, treated with WCM for 24 hours, were harvested and subjected to quantitative Real 
Time PCR for relative mRNA level analysis of downstream target proliferative genes, 
Axin2 and Cyclin D1. The transcription levels were normalized to the respective GAPDH 
levels. Statistical differences were assessed using Student’s t test (*p<0.05, **p<0.01, 
***p<0.001). 
 
3.3.2 Effect of siRNA knockdown of endogenous LRP5 and LRP6 on Wnt 
signaling in SH-SY5Y cells 
We next performed gene knockdown experiments using siRNA to validate the 
functional role of LRP5 and LRP6 in regulating Wnt signaling. As shown in 
Figure 3-2A, total β-catenin protein level was reduced only in the presence of 
Wnt3a ligands when both co-receptors were suppressed. On the other hand, the 
decrease in active β-catenin protein levels was more significant than that of total 
β-catenin both in the presence and absence of Wnt3a stimulation. 
Correspondingly, TCF/LEF-dependent TOPglow reporter activity was 
significantly decreased by 68.4 ± 7.0% and 80.6 ± 2.7% in LRP5- and LRP6- 
knockdown cells respectively (Figure 3-2B). For the transcription of downstream 
survival genes such as Axin2 and Cyclin D1, mRNA levels were significantly 
downregulated by 28.7 ± 3.8% and 28.1 ± 6.6% respectively with LRP5 
suppression and by 31.8 ± 2.7% and 41.5 ± 2.8% respectively with LRP6 
suppression (Figure 3-2C). These results suggest that endogenous LRP5 and 
LRP6 co-receptors are functionally important in modulating Wnt signaling in SH-
































































































































































































































































































































Figure 3-2. Knockdown of LRP5 or LRP6 in SH-SY5Y human neuroblastoma cells 
suppresses Wnt signaling and the transcription of downstream proliferation 
markers. (A) SH-SY5Y cells were transfected with 20nM scrambled, LRP5 or LRP6 
siRNA and treated with either LCM or WCM for 24 hours before harvested. Samples 
were subjected to Western blotting lysis buffer and probed with anti-LRP5/6, anti-total β-
catenin, anti-active β-catenin, and anti-β-actin antibodies. (B) SH-SY5Y cells were 
transfected with 20nM scrambled, LRP5 or LRP6 siRNA together with TOPglow and 
pRL-CMV Renilla plasmids and treated with LCM or WCM for 24 hours. Dual–
Luciferase activities were measured and data was represented as the mean ± S.E.M. of 
fold activation over scrambled siRNA treated with LCM. (C) SH-SY5Y cells transfected 
with scrambled, LRP5 or LRP6 siRNA and treated with WCM for 24 hours, before 
subjected to quantitative Real Time PCR for relative mRNA level analysis of 
downstream target proliferative genes, Axin2 and Cyclin D1. The transcription levels 
were normalized to the respective GAPDH levels. Statistical differences were determined 
using Student’s t test (*p<0.05, **p<0.01, ***p<0.001). 
 
3.3.3 Generation of AD cell model with Aβ challenge 
Overproduction and aggregation of Aβ has been proposed as the prime driver of 
AD [153]. Compared with other Aβ peptides, Aβ42 is the neurotoxic form and the 
main component of senile plaques. Therefore, we employed Aβ42 to induce 
toxicity in SH-SY5Y cells. To exclude the interference of FBS and phenol red in 
the cell culture medium, we introduced FBS-free, phenol red-free medium and 
determined the suitable cell count for seeding. SH-SY5Y cells with indicated cell 




 were seeded in 96-well plates and maintained 
42 
 
in FBS-free, phenol red-free F12 medium for 24 and 72 hours. 10% Triton-X100 
were added as a positive control for 100% cell death. Cell viability was evaluated 
by CCK-8 and LDH cytotoxicity assays. As shown in Figure 3-3A, obvious and 







.  In addition, cell seeding of 10
5
 provides 90% proper 
confluency under microscope. Therefore, cell count of 10
5
 was used in the 
subsequent CCK-8 and LDH cytotoxicity assays. Since Aβ42 oligomers have 
emerged as the most toxic species, we aged Aβ42 monomers for 1 day into 
oligomers in F12 medium and treated SH-SY5Y cells with indicated 
concentrations for 24 hours and 72 hours as shown in Figure 3-3B. Despite the 
positive control suggested a significant decrease in cell viability, Aβ42 oligomers 
up to concentration of 5µM did not show any toxicity to the cells.  Moreover, 
Aβ42 fibrils have also been indicated to induce progressive dystrophy and cell 
death in human cortical neurons [154]. Therefore, we introduced Aβ42 fibrils and 
increased the concentration to 10µM to examine cell viability. To preclude the 
possibility of interference, cells were starved in FBS-free, phenol-red F12 
medium for 20 hours before Aβ was added. As shown in Figure 3-3C, both Aβ42 
oligomers and fibrils did not have any effect on cell survival. We then tried to age 
Aβ42 for 7 days before added into incubation with SH-SY5Y cells. However, 
Aβ42 oligomers and fibrils still failed to induce any cytotoxicity even at the 
concentration of 50µM (Figure 3-3D). Among all the Aβ derivatives, Aβ25-35, is 
the shortest fragment that represents the biologically active region and retains the 
toxicity of the full-length Aβ peptide [155]. Hence, we aged Aβ25-35 for 1, 4, 7 
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days to form oligomers and fibrils at 4˚C and 37˚C respectively. 5, 10, 25 and 
50µM of Aβ25-35 oligomers and fibrils were incubated with SH-SY5Y cells for 
72 hours before assessment with CCK-8 and LDH assays. However, as shown in 
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Figure 3-3. Generation of AD cell model with Aβ challenge. (A) SH-SY5Y cells with 
indicated cell counts were seeded in 96-well plates and incubated in FBS-free, phenol 
red-free F12 medium for 24 and 72 hours. 10% Triton-X100 was added 10 min before 
harvest as the positive control with 100% cell death. Cells were then subjected to CCK-8 
cell viability and LDH cytotoxicity assays. (B) Aβ42 was aged at 4˚C for 1 day into 
oligomers. Indicated concentrations of Aβ42 oligomers were incubated with SH-SY5Y 
cells in FBS-free, phenol red-free F12 medium for 24 and 72 hours before examination 
with CCK-8 cell viability and LDH cytotoxicity assays. (C) Aβ42 was aged at 4˚C for 1 
day into oligomers and aged at 37˚C for 1 day into fibrils. 5µM and 10µM Aβ42 
oligomers and fibrils were added to SH-SY5Y cells for 72 hours. Cells were then 
subjected to CCK-8 cell viability and LDH cytotoxicity assays. (D) SH-SY5Y cells were 
starved in FBS-free, phenol red-free F12 medium for 20 hours before incubation for 72 
hours with 50µM Aβ42 oligomers and fibrils aged for 7 days. Cells were then assessed 
for CCK-8 cell viability and LDH cytotoxicity. (E) Aβ25-35 was aged for 1, 4, 7 days 
into oligomers and fibrils. Indicated concentrations of Aβ25-35 oligomers and fibrils 
were added to pre-starved SH-SY5Y cells for 72 hours. Cells were then subjected to 




3.3.4 LRP5 and LRP6 overexpression rescues SH-SY5Y cells from 
neurotoxicity caused by hydrogen peroxide-induced oxidative stress 
After failing to generate AD cell model with Aβ challenge, we insulted cells with 
oxidative stress as the alternative AD model. Oxidative stress has been indicated 
to be an early event in AD [156]. In the post mortem AD brain, increased 
oxidative stress markers have been found to be associated with the loss of 
neuronal viability [157-159]. Moreover, Aβ has been reported to increase 
hydrogen peroxide level in cultured neuronal cells and cause cytotoxicity [160]. 
To induce oxidative stress in SH-SY5Y cells, cells were subjected to hydrogen 
peroxide treatment at concentrations ranging from 10 to 50μM and examined for 
cytotoxicity. Figure 3-4A showed that cell viability decreased in a concentration-
dependent manner when cells were cultured with 10-50μM H2O2, as compared to 
vehicle control.  LRP5 and LRP6 overexpression, however, were able to 
ameliorate this hydrogen peroxide-induced cell cytotoxicity at all concentrations 
used.  To further confirm the protection against H2O2-mediated toxicity, cell cycle 
analysis of transfected cells was performed using flow cytometry.  Hydrogen 
peroxide treatment resulted in increased Sub G0/G1 apoptosis population. 
However, the percentage of cells in the Sub G0/G1 phase was significantly 
reduced in LRP5- and LRP6-transfected cells following the same hydrogen 
peroxide treatment (Figure 3-4B). We further investigated the influence of the 
Wnt co-receptors on hydrogen peroxide-induced apoptosis by examining the 
expression of the key apoptotic mediators caspase 3 and 7. When SH-SY5Y cells 
were incubated with H2O2 alone, the cleavage of pro-caspase 3 and pro-caspase 7 
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into the active subunits was elevated in a concentration-dependent manner with 
hydrogen peroxide treatment (Figure 3-4C). In contrast, LRP5 and LRP6 
overexpression was able to reduce the levels of cleaved caspase 3 and 7. 
Specifically, at 50μM H2O2 treatment, cleaved caspase 3 was decreased by 35.2% 
and 64.7% and caspase 7 was decreased by 66.5% and 79.6% by LRP5 and LRP6 
overexpression respectively. The β-actin protein level, as an internal control, was 
almost the same in all samples.  
(A) 





































































































































































































































































































































































Figure 3-4. LRP5 and LRP6 overexpression rescues SH-SY5Y cells from 
neurotoxicity caused by hydrogen peroxide-induced oxidative stress. SH-SY5Y cells 
were transfected with pcDNA3.1-LRP5 or pCS2+-LRP6 plasmids and treated with 
various concentration of hydrogen peroxide in WCM for 24 hours before analyzed for 
cell viability assessment. (A) Cell viability was measured by MTT assay. The data were 
presented as the mean (% of non-treated group) ± S.E.M. LRP5 or LRP6 overexpression 
cells were compared to respective vector overexpression group in each treatment group 
and the statistical significance was measured with Student’s t test (*p<0.05, **p<0.01, 
***p<0.001). (B) Cells were stained with PI before subjected to flow cytometry for cell 
cycle analysis. The Sub G0/G1 apoptosis populations were plotted as the percentage of 
total cell counts and data were presented as mean ± S.E.M. from three independent 
experiments.  The measurement of statistical significance was the same as described in 
(A).  (C) Processing of pro-caspases 3 and 7 into active cleaved caspases were assessed 
by specific antibodies against active caspases 3 and 7. Quantitative densitometry of 
cleaved caspases 3 and 7 under the treatment of 50μM H2O2 was normalized to respective 
β-actin. The data represented the mean values ± S.E.M. and statistical significance was 




3.3.5 LRP5 and LRP6 overexpression inhibits GSK3β activity and reduces 
tau phosphorylation in SH-SY5Y cells 
The presence of extracellular Wnt ligands activates Wnt signaling pathway and 
leads to the inhibition of GSK3β activity by phosphorylating GSK3β at Ser9 
residue [143]. Consistent with this finding, our Western blotting result showed an 
increase in GSK3β Ser9 protein levels when Wnt3a ligands were present, 
indicating a decrease in GSK3β activity (Figure 3-5A). Since  GSK3β has been 
identified as one of the main kinases phosphorylating tau at pathogenic residues 
implicated in AD [146,147], the decrease in GSK3β activity in our studies was 
also accompanied by a reduction in tau phosphorylation as examined using the 
phosphospecific antibody against tau Ser202/Thr205 (AT8) [161,162]. 
Remarkably, LRP5 and LRP6 overexpression augmented the reduction in GSK3β 
activity by 46.7% and 27.4% (1.9- and 1.4-fold increase in GSK3β Ser9 protein 
level) and reduced tau reactivity against the AT8 antibody further by 65.1% and 
































































































































Figure 3-5. LRP5 and LRP6 overexpression inhibits GSK3β activity and reduces tau 
phosphorylation in SH-SY5Y cells. SH-SY5Y cells were transfected with LRP5 or 
LRP6 expression plasmids and treated with either LCM or WCM for 24 hours. (A) Cells 
were then subjected to Western blotting analysis and probed with anti-GSK3β Ser9 
antibody or anti-phosphorylated tau AT8 antibody. (B) Quantitative densitometry of 
GSK3β Ser9 and Ser202/Thr205 phosphorylated tau was normalized to that of respective 
β-actin. The data represented the average ± S.E.M. and statistical significance was 
assessed with Student’s t test (*p<0.05, **p<0.01, ***p<0.001). 
 
3.4  Discussion 
Aberrant Wnt inhibition has been implicated to play a vital role in the 
pathogenesis of AD in transgenic animal models as well as AD patients 
[133,134,137]. Activation of the repressed Wnt signaling by introducing Wnt 
ligands or inhibiting the activity of GSK3β has been shown to effectively rescue 
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neurodegeneration and improve behavioral impairments both in vitro and in vivo 
[143,144]. However, the link in transducing the upstream signaling from 
extracellular Wnt ligands to intracellular GSK3β still remains to be established. In 
this study, we found that overexpression of Wnt co-receptors LRP5 and LRP6 
elevates cellular β-catenin protein level in the presence of Wnt ligands. 
Particularly, the increase of active β-catenin is more prominent. Active β-catenin 
is the dephosphorylated population that accumulates and translocates into nucleus 
to bind to TCF/LEF [123]. As a result, the transcription of downstream survival 
genes, Axin2 and Cyclin D1 [163,164], is upregulated. This finding suggests that 
LRP5 and LRP6 play an important role in positively regulating Wnt activity and 
facilitating the expression of proliferative genes.  On the other hand, silencing of 
LRP5 or LRP6 results in reduced total and active β-catenin, and decreased 
transcription of downstream proliferative genes, which further supports the 
essential role of LRP5 and LRP6 in increasing neuronal survival gene expression 
through Wnt pathway. 
To evaluate the neuroprotective role of LRP5 and LRP6 in AD, we introduced 
oxidative stress using hydrogen peroxide. Aβ aggregation-induced oxidative 
stress has been reported to be involved in AD by causing cytotoxicity [165-167]. 
Previously, it had been reported that activation of Wnt activity by Wnt3a ligand 
exerts a neuroprotective role in overcoming Aβ-induced oxidative stress and 
neurotoxic effects [143]. In the present study, our results indicate that hydrogen 
peroxide induced a significant reduction in cell viability in a dose-dependent 
manner, in concordance with the increase in the Sub G0/G1 apoptotic population. 
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Overexpression of LRP5 and LRP6 was able to restore cell viability and decrease 
apoptotic population at a concentration up to 50μM. Additionally, the protective 
effects of the two Wnt co-receptors were also evident through the protein levels of 
apoptotic mediators. Evaluation of caspase 3 and 7 activity clearly indicates that 
cells treated with hydrogen peroxide were affected by apoptosis at the 
concentration of 40 and 50μM. Taken together, our results highlight the 
importance of Wnt co-receptors LRP5 and LRP6 in rescuing neuronal cell from 
hydrogen peroxide-induced neurotoxicity and DNA fragmentation. 
 
Tau hyperphosphorylation is an important hallmark for NFT formation and 
subsequent AD progression. GSK3β has been implicated as one of the main tau 
phosphorylation kinases in the AD etiology [138,139]. Studies have shown that 
inhibition of GSK3β activity, via either the GSK3β inhibitor lithium or Wnt 
ligands, reduced tau phosphorylation both in vitro and in vivo [168]. Since LRP5 
and LRP6 are the direct regulators upstream of GSK3β in Wnt/β-catenin pathway, 
we examined the role of LRP5 and LRP6 in modulating the activity of GSK3β 
and tau phosphorylation. Our finding that overexpression of LRP5 and LRP6 
inhibited GSK3β activity resulting in decreased levels of phosphorylated tau 
suggests that LRP5 and LRP6 protect cells from tau hyperphosphorylation 




Although LRP5 and LRP6 are highly homologous and both serve as the co-
receptors for Wnt cascade, numerous reports suggest that their role in regulating 
Wnt signaling may not be equivalent [114,150]. LRP6 deficient mice are perinatal 
lethal, whereas LRP5 knockout mice are viable and can grow into adulthood 
[112,129]. Here, we observed a more significant upregulation of β-catenin and 
downstream proliferation genes in the cells overexpresseing LRP6 than LRP5. 
Similarly, we found that knockdown of LRP6 repressed Wnt activity to a greater 
extent than knockdown of LRP5. As a result, LRP6 restored oxidative stress-
induced neurotoxicity and tau phosphorylation to a greater extent than LRP5. Our 
results suggest that these two co-receptors both exhibit protective role against 
neurotoxicity and that more pronounced neuroprotective role was observed with 
LRP6. 
 
3.5  Conclusion 
In summary, we present the first molecular study that shows the neuroprotective 
role of Wnt co-receptors LRP5 and LRP6 in improving neuronal survival and 
reducing tau phosphorylation through upregulating Wnt signaling. Our findings 
suggest that Wnt co-receptors LRP5 and LRP6 could be further explored as novel 





CHAPTER 4. CHARACTERIZATION OF THE INTERACTION 
BETWEEN LRP5/6 AND APOLIPOPROTEIN E PROTEINS  
 
4.1  Introduction 
Although several susceptibility genes have been associated with AD, so far only 
apoE ε4 allele is recognized as the prime genetic risk factor for LOAD with high 
confidence [33,34]. The apoE gene is highly polymorphic, resulting in three 
common isoforms apoE2, apoE3 and apoE4 [53]. Compared to the prevalent apoE 
ε3 allele, ε4 increases AD risk while ε2 is regarded to be protective. ApoE2 and 
apoE3 are more efficient in redistributing lipids among CNS cells for normal lipid 
homeostasis, repairing injured neurons and maintaining synaptic connections 
while apoE4 may exert detrimental effects in the processes. These isoform-
specific effects are mediated by its receptor, LDL receptor family.  
 
As mentioned in Chapter 1, the LDL receptor family includes core members such 
as LRP1, apoER2, LDLR, as well as more distantly related ones such as LRP5, 
LRP6 and SorLA/LR11. So far only two members of this family have been linked 
with AD by human genetic studies, LRP1 [169] and LRP6 [140,152]. The 
distantly related members, LRP5 and LRP6, are the essential co-receptors of the 
Wnt/β-catenin pathway. As dysregulated Wnt signaling plays a vital role in AD 
pathology, it is possible that apoE exerts the isoform-specific neurobiological 
effects through LRP5 and LRP6. However, there is no direct evidence of the 
57 
 
interaction between LRP5/6 and apoE isoforms, albeit LRP5 has been reported to 
facilitate the internalization of apoE-enriched β-migrating very low density 
lipoprotein [170]. 
 
Therefore, in this chapter, we aimed to address the missing link between LRP5/6 
and apoE isoforms and its effect on Wnt signaling. We herein identified the 
interaction between LRP5/6 and apoE isoforms with co-immunoprecipitation 
assays. Furthermore, we found that the interaction between LRP5 and apoE 
isoforms inhibited the activation ability of LRP5 on Wnt/β-catenin activity. In 
addition, the effects of the interaction on GSK3β were isoform-specific with 
apoE4 inducing the strongest inhibition. Taken together, the findings from this 
chapter not only provide a bridge linking Wnt signaling and apoE pathology 
together, but also present an interesting research direction for better understanding 
of the mechanisms underlying AD.  
 
4.2  Materials and Methods 
4.2.1  Cell culture and reagents 
Cell culture and plasmid transfection with human neuroblastoma SH-SY5Y cells 
and HEK 293T cells were performed in the same manner as reported in Section 
3.2.1 of Chapter 3. For overexpression plasmids, the source of pcDNA3.1–LRP5 
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and pCS2+–LRP6 was mentioned in Section 3.2.1 of Chapter 3. pCMV.–apoE2 
and pCMV.–apoE4 were kindly given by Dr. Panagiotis Takis Athanasopoulos 
from University of Wolverhampton, United Kingdom.  
 
4.2.2  Mutagenesis 
200ng pCMV.–apoE2 plasmid was used as the DNA template to generate 
pCMV.–apoE3 using QuikChangeTM Site-Directed Mutagenesis Kit (Stratagene, 
La Jolla, CA). Mutagenesis primers were designed as shown in Table 4-1. The 
following reaction mixture was prepared on ice (Table 4-2). The reaction tube 
was then placed on the thermal cycler Flexigene (Techne, Staffordshire, UK) with 
30 sec-denaturation at 95˚C, followed by a total of 18 cycles consisting of 30 sec-
denaturation at 95˚C, 1 min-annealing at 55˚C and 2 min-extension at 68˚C. At 
the end, the reaction was cooled down on ice for 2 min before DpnI restriction 
enzyme digestion at 37˚C for 1 hour to eliminate apoE2 template. 1μL of DpnI-
treated DNA was then subjected to bacterial transformation. 
 
Table 4-1 Primers used for site-directed mutagenesis from apoE2 to apoE3 
Primer Name Sequence 
apoE2to3 forward 5'-GAT GAC CTG CAG AAG CGC CTG GCA 
GTG TAC-3' 





Table 4-2 Reagents used for mutagenesis 
Reagents Volume 
10x Pfu Buffer 5μL 
pCMV.–apoE2 (100ng/μL) 2μL 
apoE2to3 forward (100ng/μL) 1.25μL 
apoE2to3 reverse (100ng/μL) 1.25μL 
dNTP (10mM) 1μL 
Turbo/Promega Pfu DNA 
polymerase 
1μL 
double-distilled H2O (ddH2O) 38.5μL 
total 50μL 
 
4.2.3  Bacterial transformation 
1μL of mutagenesis product was transferred to a clean 1.5mL Eppendorf tube and 
mixed with 50μL DH5α bacterial strain on ice, followed by gently tapping. The 
bacteria-DNA mixture was incubated on ice for 30 min and then heat-shocked at 
42˚C for 45 sec. The mixture was then cooled on ice for 2 min and added with 
500μL pre-warmed LB Broth (Acumedia, Lansing, MI). The tube was shaken at 
37˚C for 1 hour. Bacterial pellet was spun down under 4,000rpm for 5 min and 
500μL supernatant was removed. The rest of supernatant was mixed with 
bacterial pellet and spread onto LB agar plate with 100μg/mL ampicillin. LB agar 




4.2.4  Restriction enzyme digestion 
10μL out of 30μL plasmids with minipreparation (miniprep) was subjected to 
restriction enzymes double-digestion with 10 units of XhoI (New England Biolabs, 
Beverly, MA) and 10 units of HindIII (New England Biolabs, Beverly, MA) in a 
20 μL reaction volume. The reaction mixture was incubated at 37˚C for 2 hours 
before being subjected to gel electrophoresis.  
 
4.2.5  Agarose gel electrophoresis 
1g agarose (Invitrogen, Carlsbad, CA) was weighed and dissolved into 100mL 
TAE (Tris-Acetate-EDTA) buffer (40mM Tris, 20mM acetate acid, 2mM EDTA, 
pH 8.3) in a 500mL conical flask. The agarose-TAE solution was stirred on a 
heated magnetic stirrer under 90˚C until completely melted. The melted agarose 
was allowed to cool sufficiently before adding SYBR
®
 Safe DNA Gel Strain 
(Invitrogen, Carlsbad, CA) and pouring into a cast. A comb was placed in the cast 
to create wells for loading samples and gels were completely set before use. DNA 
samples were mixed with loading buffer (New England Biolabs, Beverly, MA) 
before transferring into the wells. 1kb DNA ladder (New England Biolabs, 
Beverly, MA) was loaded to indicate DNA molecular weight. Gel electrophoresis 
was performed under 120V for 30 min before visualization using ChemiDoc 
XRS
+




4.2.6  Western blotting analysis 
Western blotting assay was performed with the same manner as described in 
Section 3.2.4 of Chapter 3 with modified lysis buffer (25mM Tris, 2.5mM EDTA, 
2.5mM EGTA, 100mM NaCl, 20mM  C3H7Na2O6P, 20mM NaF, 1mM Na3VO4, 
10mM Na4P2O7, 0.5% deoxycholate, 1% Triton X-100, pH7.4) supplemented 
with protease inhibitor cocktail tablet (Roche Diagnostics, Germany). ApoE 
antibody was purchased from Millipore (Billerica, MA). This apoE antibody was 
raised against a synthetic peptide corresponding to amino acids surrounding the 
polymorphic amino acid position 158 of apoE and recognizes all three human 
apoE isoforms. 
 
4.2.7  Co-immunoprecipitation 
0.5mL of total cell lysate containing 1mg of protein was incubated with apoE 
antibody and protein G agarose beads (Roche Diagnostics, Germany) at 4˚C on a 
turning roller overnight. The protein G agarose beads were washed with lysis 
buffer 3-4 times on the following day. Samples were then subject to SDS-PAGE 




4.2.8  Dual luciferase reporter assay 
SH-SY5Y cells (2.5x10
5
) were seeded in 24-well plates overnight and transfected 
with 1μg LRP5 or LRP6 expression plasmids,  1μg apoE2, apoE3 or apoE4 
expression plasmids, 1μg reporter construct (TOPglow) and 0.04μg pRL-CMV 
Renilla control plasmids. After 6 hours of transfection, the medium was replaced 
with either LCM or WCM. Cells were harvested and the fluorescent activity was 
determined and calculated with the same manner as described in Section 3.2.3 of 
Chapter 3.  
 
4.2.9  Statistical analysis 
All data was presented as an average of three independent experiments ± S.E.M. 
Statistical analysis was performed using the one-way ANOVA with Dunnett’s 
post-hoc analysis (SPSS, Chicago, IL) and significance was assumed at p < 0.05. 
 
4.3  Results 
4.3.1  Site-directed mutagenesis of pCMV.–apoE2 to generate pCMV.–apoE3  
ApoE3 differs from apoE2 in amino acid residue 158, with apoE3 possessing 
Arg158 and apoE2 having Cys158. Therefore, to generate apoE3 plasmid, we 
performed site-directed mutagenesis with Turbo and Promega Pfu DNA 
polymerase using pCMV.–apoE2 as DNA template. As shown in Figure 4-1A, 
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after 18 cycles of amplification, a clear and abundant DNA band having similar 
molecular weight as pCMV.–apoE2 appeared in both mutagenesis products 
amplified by Turbo and Promega Pfu. 1μL of each mutagenesis product was then 
transformed into DH5α bacterial strains and three colonies each were picked up 
for restriction enzymes XhoI and HindIII double-digestion on the following day. 
As shown in agarose gel electrophoresis (Figure 4-1B), all the colonies presented 
one 1457bp and one 3274bp DNA bands as expected. Colony 1 amplified by 
Turbo Pfu and Colony 2 amplified by Promega Pfu were sent for sequencing to 
validate DNA sequences with apoE sequencing primers (Table 4-3). The 
sequencing results were aligned with Homo sapiens apoE3 sequence (NCBI 
Reference Sequence: NM_000041.2) with Basic Local Alignment Search Tool 
(BLAST) on the National Center for Biotechnology Information (NCBI) website. 
As shown in Figure 4-1C, the DNA sequence of apoE3 Colony 2 amplified by 
Promega Pfu (shown as Query 1 in the result) was concordant with the Homo 
sapiens apoE3 sequence (shown as Subject 1 in the result) from 541bp to 954bp. 
In Figure 4-1D, the DNA sequence of apoE3 Colony 2 amplified by Promega Pfu 
corresponds to 1bp–584bp of Homo sapiens apoE3 sequence, suggesting that the 
apoE3 plasmid from Colony 2 amplified by Promega Pfu possessed the correct 
apoE3 DNA sequence. Therefore, this colony of transformed bacteria was 





(A)                                                   (B) 
                  






(D) Sequencing result with apoE reverse primer 
 
Figure 4-1. Site-directed mutagenesis of pCMV.–apoE2 to generate pCMV.–apoE3. 
(A) pCMV.–apoE2 was used as DNA template to perform site-directed mutagenesis. 
Two types of High Fidelity Pfu DNA polymerase, Turbo Pfu and Promega Pfu, were 
employed to yield pCMV.–apoE3. After 18 cycles of amplification, 5μL mutagenesis 
products were subjected to 1% agarose gel electrophoresis for analysis. 200ng 
pCMV.apoE2 plasmid was loaded as an indicator of the correct molecular weight. (B) 
1μL of both mutagenesis products were transformed into DH5α strains. The following 
day, three colonies each from Turbo and Promega Pfu amplification products were 
selected and plasmids were extracted with miniprep process before digestion with XhoI 
and HindIII. Colony 1 from Turbo Pfu amplification product and Colony 2 from Promega 
Pfu mutagenesis product were sent for sequencing. The sequencing results of Colony 2 
amplified with Promega Pfu were presented in (C) and (D). The DNA sequence from 
mutagenesis product was shown as Query 1 and Homo sapiens apoE3 sequence was 




Table 4-3 Primers used for sequencing pCMV.apoE3. 
Primer Name Sequence 
apoE forward 5'-CCT CCG CGA TGC CGA TGA CC -3' 
apoE reverse 5'-CAC GCG GCC CTG TTC CAC C-3' 
 
4.3.2  LRP5 and LRP6 interact with all three apoE isoforms  
To determine the binding affinity between LRP5/6 and apoE isoforms, we 
performed co-immunoprecipitation assays. LRP5/6 expression plasmids together 
with apoE2, 3 or 4 were co-transfected into HEK293T cells. Cell lysates were 
immunoprecipitated down by apoE antibody and subjected to Western blotting 
assay. As shown in Figure 4-2A, LRP5 and LRP6 were detected in all the protein 
complexes pulled down by apoE antibody, which indicated the interaction 
between LRP5/6 and all three apoE isoforms. Since LRP5 is a less known Wnt 
co-receptor, we decided to focus our research on the interaction between LRP5 
and apoE isoforms. To identify the interaction in neuronal cell lines, LRP5 and 
apoE isoforms were transiently co-transfected in human neuroblastoma SH-SY5Y 
cells. Figure 4-2B showed that LRP5 binds to apoE3 and 4 in SH-SY5Y cells 










Figure 4-2. Detection of the interaction between apoE isoforms and LRP5/6. (A) 
HEK293T cells were overexpressed with LRP5 or 6 plasmids together with human apoE 
isoforms 2, 3, 4 plasmids. Equivalent lysates were immunoprecipitated (IP) with apoE 
antibody, followed by immunoblotting (IB) with LRP5 or 6 antibodies (upper panels). 
Total lysates were probed with specific antibodies, addressing the protein levels of 
LRP5/6, apoE 2/3/4, and β-actin. (bottom panel). (B) SH-SY5Y cells were overexpressed 
with apoE isoforms and LRP5 plasmid. The lysate was subjected to co-IP and Western 
blotting assays as described above. 
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4.3.3  The interaction between LRP5 and apoE isoforms disrupts the 
activation ability of LRP5  
Since LRP5 acts as Wnt co-receptor to transduce Wnt signaling downstream, we 
asked the question whether binding with apoE isoforms would affect its ability to 
activate Wnt/β-catenin activities. TCF/LEF transcriptional activities in the SH-
SY5Y cells co-transfected with LRP5 and apoE 2/3/4 were analyzed using a 
TCF/LEF-responsive luciferase reporter vector (TOPglow).  In the absence of 
apoE isoforms, TCF/LEF transcriptional activities in the cells transfected with 
LRP5 were significantly increased compared to vector control. With the 
overexpression of apoE isoforms together with LRP5, however, TCF/LEF 
transcriptional activities were significantly decreased compared to the one 
transfected with LRP5 alone (Figure 4-3).  































Figure 4-3. The interaction between LRP5 and apoE isoforms disrupts the 
activation ability of LRP5. SH-SY5Y cells were transfected with apoE isoforms and 
LRP5 expression plasmids together with TOPglow and pRL-CMV Renilla plasmids and 
treated with LCM or WCM for 24 hours. Wnt3a-induced luciferase activities were 
measured with Dual–Luciferase Reporter Assay Kit. Fold induction was presented in the 
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bar graph as of luciferase readings of WCM treatment over LCM treatment. Values 
represented the average (n=3) ± S.E.M.. Statistical differences were assessed using one-
way ANOVA with Dunnett’s post-hoc analysis (*p<0.05, **p<0.01, ***p<0.001).  
 
4.3.4  Effect of the interaction between LRP5 and apoE isoforms on GSK3β 
activity  
GSK3β is another major player in AD pathology whose activity is partially 
regulated by Wnt signaling. Therefore, we assessed whether GSK3β activity was 
affected by the interaction between LRP5 and apoE isoforms. Consistent with the 
finding in Chapter 3, Western blotting showed an increase in GSK3β Ser9 protein 
levels when LRP5 was overexpressed, indicating a decrease in GSK3β activity. 
For cells transfected with apoE isoforms alone, we observed a decrease in GSK3β 
activity in apoE4 overexpressing cells, but not in those transfected with apoE2 
and apoE3. When LRP5 was co-expressed together with apoE isoforms, a 
significant decrease in GSK3β activity was observed in apoE3 and apoE4 
expressing cells whereas no significant protein level change was seen for apoE2 





Figure 4-4. Effect of the interaction between LRP5 and apoE isoforms on GSK3β 
activity. SH-SY5Y cells were transfected with LRP5 together with apoE isoforms 
expression plasmids. Cells were then subjected to Western blotting analysis and probed 
with anti-LRP5, anti-apoE, anti-GSK3β Ser9 or anti-β-actin antibodies. 
 
4.4  Discussion 
LDL receptor family constitutes a group of structurally related cell surface 
receptors that recognize and bind to several structurally diverse extracellular 
ligands [108,109]. LDL receptor family has recently emerged as prominent 
players in neurodegenerative diseases due to its role as apoE receptors. However, 
the mechanism underlying this genetic predisposition is still largely unknown.  On 
the other hand, abnormally regulated Wnt signaling has recently received 
significant attention for its role in AD pathology. LRP5 and LRP6, the distantly 
related members of LDL receptor family, also function as the essential Wnt co-
receptors. However, the direct evidence of the binding between LRP5/6 and apoE 




We herein show for the first time that LRP5 and LRP6 bind to all three common 
apoE isoforms in HEK293T cells. In neuronal cell lines, SH-SY5Y human 
neuroblastoma cells, LRP5 strongly bound to apoE3 while a relatively weak 
interaction was observed between LRP5 and apoE4. The interaction between 
LRP5 and apoE2 was not seen in SH-SY5Y cells, which might be due to the low 
affinity beyond the detection limit.  
Since LRP5 is the important Wnt co-receptor and apoE4 has been reported to 
inhibit Wnt7a-induced TCF/LEF transcriptional activity [137], we examined 
whether the interaction between LRP5 and apoE isoforms had any effect on Wnt 
signaling. Consistent to the previous studies with Wnt7a, our results showed that 
transfected apoE2, 3, and 4 reduced Wnt3a luciferase activities compared to basal 
conditions. However, Caruso et al. reported that apoE4 displayed a strong 
inhibitory effect in Wnt signaling whereas in our results the inhibitory effects 
were comparable among all the isoforms [137]. This might be due to the 
differences between Wnt ligands since it has been previously showed that Wnt3a 
and Wnt7a have different binding specificities for Fzs [171]. Furthermore, our 
results demonstrated that expression of apoE isoforms together with LRP5 
abolished the activation ability of LRP5 on Wnt signaling. Taken together, our 
observation indicated that apoE isoforms regulate Wnt signaling and the 
interaction between LRP5 and apoE isoforms disrupts the co-activation ability of 




Another important mediator of Wnt signaling is GSK3β, which has also been 
implicated in different aspects of AD pathophysiology. In addition to its ability to 
phosphorylate tau, GSK3β activity has been shown to influence neuronal 
proliferation and differentiation [172]. Defects in above processes lead to an 
impairment of memory which is one of the main features of AD. To address the 
issue whether the interaction between LRP5 and apoE isoforms affects GSK3β 
activity, we performed Western blotting assay and determined the protein amount 
of Ser9 phosphorylated GSK3β. Our results first showed that apoE4 decreased 
GSK3β activity significantly while apoE2 and apoE3 did not. Second, the 
interaction between LRP5 and apoE regulated GSK3β activity in an isoform-
specific manner. A further reduction in GSK3β activity was seen when apoE4 was 
co-transfected with LRP5. ApoE3 was able to inhibit GSK3β activity only when 
LRP5 was co-expressed, whereas apoE2 did not show any inhibitory effect even 
with the enforced expression of LRP5. The GSK3β activity results in Figure 4-4 
were not concordance with Wnt3a-induced TCF/LEF transcriptional activities in 
Figure 4-3, probably due to the absence of exogenous Wnt ligands and differences 
in the cell harvest time. As demonstrated by Cedazo-Minguez et al., recombinant 
apoE3 and apoE4 activated GSK3β at 1 hour [173]. At 5 hours, however, the 
activation effect was not seen with apoE3 while an inhibitory effect was observed 
with apoE4 [173]. Therefore, detailed studies with different transfection durations 




4.5  Conclusion 
Taken together, our results provide direct evidence on the interaction between 
Wnt co-receptors LRP5/6 and all three common apoE isoforms, namely apoE2, 
apoE3 and apoE4. This piece of data not only proves that LRP5 and LRP6 are the 
receptors of apoE isoforms, but also provides a link between Wnt signaling and 
apoE pathology. In addition, we also showed that the interaction between LRP5 
and apoE isoforms disrupts the activation ability of LRP5 and exerts isoform-
specific effects on GSK3β activity. The findings from this chapter provide an 
interesting direction in understanding the mechanism underlying AD pathology 


















CHAPTER 5. APOLIPOPROTEIN E4 DISRUPTS NORMAL 
MITOCHONDRIAL DYNAMICS THROUGH BINDING TO LOW-
DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 5/6 IN SH-
SY5Y CELLS 
 
5.1  Introduction 
Mitochondria are highly dynamic organelles, adopting different shapes from giant 
tubular network to small punctate pattern of separated mitochondria through 
fusion and fission processes [174,175]. In addition to morphology, fusion and 
fission processes also regulate mitochondrial functions including energy 
production, generation of ROS and cell survival [176]. Due to high dependence 
on mitochondrial energy production and complex morphology, neurons are 
especially sensitive to mitochondrial dysfunction [177]. Alterations in 
mitochondrial dynamics significantly impair neuronal functions which have been 
associated with neurodegenerative diseases including AD [106,107,178]. 
 
Mitochondrial fusion is a two-step process, with outer membrane fusion followed 
by inner membrane fusion. These events result in the mixing of membranes, 
intermembrane space and matrix [179]. In mammals, two large transmembrane 
GTPases, Mfn 1 and 2, are essential for mediating outer membrane fusion 
[180,181]. These two Mfns form homotypic and heterotypic complexes, which 
provide a mechanism for organelle tethering [96,182]. Subsequently, it is possible 
that GTP hydrolysis-driven conformational changes mediate the outer membranes 
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to fuse. Another GTPase, OPA1, is required for mediating inner membrane fusion. 
Cells depleted of either Mfns or OPA1 completely lose the ability of 
mitochondrial fusion [96,183] (Figure 5-1). On the other hand, mitochondrial 
fission process is mediated by two classes of proteins. The protein in the first 
class, Drp1, mostly resides in cytosol, which is recruited to the mitochondrial 
fission puncta by the second class of molecules including Fis1 (Figure 5-1). Drp1 
is a central player essential for mitochondrial fission in most types of cells. 
Knockdown with RNA interference or expression of a dominant-negative variant 
of Drp1 leads to extensions in the length of mitochondrial tubules [99,102]. 
Similar to dynamin, the GTPase domain in Drp1 is likely to hydrolyze GTP and 
provide mechanical force to assemble into high-order helical structures [184,185]. 
The self-assemble spiral structures correspond to the Drp1 puncta on 
mitochondria and cause a large constriction [186-188].  
 
Figure 5-1. Schematic representation of mitochondrial fusion and fission processes. 




Despite growing evidence suggesting that mitochondrial fusion and fusion 
processes are disrupted in AD neurons, the molecular basis underlying the 
abnormalities in mitochondrial dynamics remains to be investigated. The main 
genetic risk factor for LOAD apoE4 has been repeatedly reported to induce 
mitochondrial dysfunction [81,83,190]. Therefore, it is noteworthy to know 
whether apoE4 also participates in abnormally regulating mitochondrial dynamics. 
 
In this study, we showed that overexpression of apoE4 in SH-SY5Y human 
neuroblastoma cells increased the levels of mitochondrial fission proteins Drp1 
and Fis1 and reduced the level of mitochondrial fusion protein Mfn2. 
Subsequently, we observe that mitochondria displayed swollen and fragmented 
morphology under the confocal microscopy. To understand this mechanism 
underlying mitochondrial fission, we demonstrate a direct interaction between 
apoE4 and LRP5/6 in both HEK293T and SH-SY5Y cell lines using co-
immunoprecipitation assay. This interaction could be disrupted by LRP5/6 
inhibitor DKK1. Using DKK1 to dissociate apoE4 and LRP5/6, we observed a 
reduction in the elevated protein levels of Drp1 and Fis1 and an increase in the 
repressed Mfn2 protein level. This dissociation subsequently led to the restoration 
of the normal mitochondrial dynamics. Taken together, our data suggest that 
apoE4 alters mitochondrial dynamics through binding to LRP5/6 and disruption 





5.2  Materials and Methods 
5.2.1  Cell culture and reagents 
SH-SY5Y human neuroblastoma cells and HEK 293T cells were cultured and 
transfected with the same manner as reported in Section 4.2.1 of Chapter 4.  
 
5.2.2  Polymerase Chain Reaction (PCR) 
ApoE4 fragment (apoE4 1-272) was amplified with specific primers (Table 5-1) 
using a Thermal Cycler (Techne, Staffordshire, UK). Amplification reagents were 
prepared in a sterile 0.2mL tube on ice as follows (Table 5-2). The amplification 
tube was placed in the Thermo Cycler and denatured at 95˚C for 10 min, followed 
by 30 cycles of amplification with DNA denaturation at 95˚C for 1 min, primer 
annealing at 62˚C for 1 min, and primer extension at 72˚C for 1 min. At the end, a 
total of 10 min extension at 72˚C was performed. 
 
Table 5-1 Primers used for amplification of apoE4 fragment 
Primer Name Sequence 
apoE4 fragment forward 5'-CCC AAG CTT GGG ATG AAG GTT CTG TGG 
GCT GCG-3' 
apoE4 fragment reverse 5'-CAT GGA TCC ATG TTA GGC CTG CAG GCG 





Table 5-2 Reagents used for PCR amplification 
Reagents Volume 
10x Pfu Buffer 5μL 
pCMV.–apoE4 (0.1μg/μL) 1μL 
apoE4 fragment primer forward 1.5μL 
apoE4 fragment primer reverse 1.5μL 
dNTP (10mM) 1μL 




5.2.3  Restriction enzyme digestion 
To generate linear DNA for ligation, 0.5μg pcDNA3.1 vector and 15μL apoE4 
fragment PCR product were digested with 10 units of HindIII (New England 
Biolabs, Beverly, MA) and 10 units of BamHI (New England Biolabs, Beverly, 
MA) at 37˚C for 5 hours. For plasmids or fragments verification, around 1 μg 
DNA was double-digested by 10 units of HindIII (New England Biolabs, Beverly, 
MA) and 10 units of BamHI (New England Biolabs, Beverly, MA) at 37˚C for 2 
hours.   
 
5.2.4  Alkaline phosphatase digestion 
Alkaline phosphatase digestion was performed before ligation to remove 5’-
phosphate group and avoid self-ligation. 1μL Calf Intestinal Alkaline Phosphatase 
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(CIP) (New England Biolabs, Beverly, MA) was diluted with 4μL ddH2O. 1μL of 
diluted CIP was added into 20μL of restriction enzyme digestion product. The 
mixture was incubated at 37˚C for 2 hours. 
 
5.2.5  Agarose gel electrophoresis 
Agarose gel electrophoresis was performed with the same manner as reported in 
Section 4.2.4 of Chapter 4.  
 
5.2.6  Gel extraction 
Gel extraction was performed with QIAquick Gel Extraction Kit (Qiagen, 
Valencia, CA) according to manufacturer’s protocol. Briefly, when adequate 
separation of bands occurred in gel electrophoresis, DNA fragments of interest 
were carefully excised under UV light ensuring as much agarose gel as possible 
has been removed. Gel slices were weighed in a clean 1.5mL microcentrifuge 
tube. Three volume of Buffer QG to one volume of gel (a gel slide of mass 0.1g 
equals to 0.1mL) was added into microcentrifuge tube and incubated at 50˚C until 
the gel completely melted. One gel volume of isopropanol was added and mixed 
into the tube before being loaded onto the column. Column bounded DNA was 




5.2.7  DNA ligation 
DNA ligation was performed with a 10μL reaction volume with T4 DNA ligase 
(Promega, Madison, WI). Restriction enzyme-digested and CIP-treated apoE4 
fragment and pcDNA3.1 vector were transferred to a clean 0.5mL 
microcentrifuge tube supplemented with 10x ligation buffer. 1μL T4 ligase was 
then added to the tube. The prepared ligation mixture was incubated at room 
temperature for 4 hours before being subjected to bacterial transformation.  
 
5.2.8  Bacterial transformation 
10μL of ligate was transferred to a clean 1.5mL Eppendorf tube and mixed with 
50μL DH5α bacterial strain on ice, followed by gently tapping. Bacterial 
transformation was performed with the same manner as described in Section 4.2.3 
of Chapter 4.  
 
5.2.9  Western blotting analysis 
Western blotting assay was performed with the same manner as described in 
Section 3.2.4 of Chapter 3. Additional antibodies were: apoE (Millipore, Billerica, 
MA), Drp1 (BD Transduction Laboratories, Franklin Lakes, New Jersey), Fis1 
(Alexis Biochemicals Corp., San Diego, CA), OPA1 (BD Transduction 
Laboratories, Franklin Lakes, New Jersey), Mfn1 (Santa Cruz Biotechnology, 
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Santa Cruz, CA), and Mfn2 (Abcam, Cambridge, MA). ApoE antibody was raised 
against a synthetic peptide corresponding to amino acids surrounding the 
polymorphic amino acid position 158 of apoE, therefore this antibody was able to 
recognize apoE4 (1-272) fragment.  
 
5.2.10  Co-immunoprecipitation 
The co-immunoprecipitation procedure was the same as reported in Section 4.2.6 
of Chapter 4. 
 
5.2.11  Confocal fluorescence microscopy 
SH-SY5Y cells (5x10
5
) were seeded on coverslips inside a 6-well plate overnight 
and transfected with 3μg LRP5 or LRP6 and 3μg apoE4 expression plasmids. 
After washing with PBS, cells were incubated with MitoTracker Red CMXRos 
(Invitrogen, Carlsbad, CA) for 10 min in the CO2 incubator, followed by fixation 
in 4% w/v paraformaldehyde for 10 min and permeabilization in 0.1% v/v 
TritonX-100 in PBS for 20 min. Samples were then blocked with 1% w/v bovine 
serum albumin (BSA) for 1 hour at room temperature. Primary antibodies (1:200 
dilution) in 0.1% w/v BSA were added into the petri dishes. After washing 3 
times with PBS, cells were incubated with secondary antibodies Alexa Fluor 488 
goat anti-mouse IgG (Invitrogen, Carlsbad, CA), Alexa Fluor 568 goat anti-mouse 
IgG (Invitrogen, Carlsbad, CA), Alexa Fluor 488 goat anti-rabbit IgG (Invitrogen, 
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Carlsbad, CA) or Chromeo™ 642 anti-Rabbit IgG - H&L (Abcam, Cambridge, 
MA) for another 1 hour. After washing with PBS 3 times, the coverslips were 
reversed and mounted onto slides. Fluorescence images were obtained using 
confocal microscopy Fluoview Fv10 (Olympus, Tokyo, Japan). 
 
5.2.12  Mitochondrial morphology analysis 
Quantitative analysis of mitochondrial morphology was achieved using Image J 
software [191,192]. All images were captured with 60x objective. Images of 10 
random fields were acquired from each treatment set at room temperature. The 
acquired mitochondrial raw images were thresholded optimally to minimize the 
noise and processed into binary pixels. The grayscale images were then subjected 
to shape distributor plugin analysis. Form Factor (FF, the reciprocal of circularity 
value) and Aspect Ratio were employed as indexes of mitochondrial 
interconnectivity. A circularity value (4π•area/perimeter2) of 1 represents circular 
and unbranched mitochondria. As the mitochondria elongate and branch, the 
circularity value decreases and approaches to 0. An Aspect Ratio (AR, major 
axis/minor axis) of 1 indicates a perfect circle and higher aspect ratio values 
indicate more elliptical and elongated mitochondria. 
5.2.13  Colocalization analysis 
For colocalization studies, 10 images of random fields for each treatment set were 
captured with 60x objective. Samples were recorded separately in each dye-
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corresponding channel. Pearson’s correlation coefficient (PCC), the correlation of 
the intensity values of the two different color pixels in a dual-channel image, was 
calculated by Fluoview Fv10-ASW to determine protein-protein colocalization.  
 
5.2.14  Detection of mitochondrial transmembrane potential  
SH-SY5Y cells (2.5x10
5
) were seeded in 24-well plates and transfected with 1μg 
apoE4 and 1μg LRP5 or LRP6 expression plasmids. After 24 hours of 
transfection, cells were incubated with 5μg/mL JC-1 fluorescence dye. 250nM 
staurosporine (STS) (Sigma-Aldrich, St Louis, MO) was added 8 hours before JC-
1 incubation as the positive control treatment group. Plates were incubated in the 
CO2 incubator for half an hour. Then cells were washed with PBS twice before 
transferred to a Nunc-Immuno MicroWell 96 well black polystyrene plate 
(Roskilde, Denmark).   JC-1 forms aggregates in the healthy mitochondria which 
display strong red fluorescent intensity with excitation and emission at 560nm and 
595nm, respectively. In unhealthy cells, JC-1 exists in monomeric form which 
shows strong green fluorescence intensity with excitation and emission at 484nm 
and 535nm, respectively. The absorbance of the red and green fluorescence was 
measured using a microplate reader (Tecan Infinite® 200 PRO, Männedorf, 
Switzerland). JC-1 ratio was calculated by dividing the readings of red 
fluorescence intensity over those of green fluorescence intensity. The experiment 




5.2.15  Statistical analysis 
Statistical significance was determined by Student’s t test or Dunnett’s One-way 
ANOVA (SPSS, Chicago, IL). p < 0.001 (***), p < 0.01 (**), p < 0.05 (*)  were 
considered to be significant. 
 
5.3  Results 
5.3.1  Molecular cloning of apoE4 fragment plasmid 
Due to unique structure, apoE4 is cleaved into C-terminal-truncated fragment 
apoE4 (1-272) inside neurons. This fragment has been found to induce 
cytotoxicity in cultured neuronal cells and cause behavioral deficits in transgenic 
mice [193-195].  Hence, to investigate the detrimental effect of apoE4 and apoE4 
fragment, we designed primers annealing to 1-272 amino acids of apoE4 and 
performed PCR amplification with pCMV.–apoE4 plasmid as template. 
pcDNA3.1 vector and apoE4 fragment PCR product were digested with HindIII 
and BamHI and treated with CIP to remove 5’ phosphate group before gel 
electrophoresis. A linear pcDNA3.1 vector with molecular weight of 5,428bp and 
a clear apoE4 fragment DNA band of 816bp were seen (Figure 5-1A). The DNA 
fragments of interest were excised under UV light and extracted using QIAquick 
Gel Extraction Kit. Extracted fragments were verified on 1% agarose (Figure 5-
1B). Next, pcDNA3.1 vector and apoE4 fragment were ligated under room 
temperature with T4 DNA ligase for 4 hours, followed by bacterial transformation. 
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On the following day, ten colonies were picked up to identify the correct clones 
for apoE4 fragment. Plasmids were extracted and digested with HindIII and 
BamHI, followed by gel electrophoresis. As shown in Fig. 5-1C, Colony 1, 2, 3, 
and 5 presented DNA bands at 816bp, the correct molecular weight for the apoE4 
fragment. Therefore, the first colony was selected and preserved in 15% glycerol 
under -80˚C. 
(A)                                                                                  (B) 





Figure 5-2. Molecular cloning of apoE4 fragment plasmid. (A) pCMV.–apoE4 was 
used as PCR template to amplify apoE4 fragment (1-272) with the annealing temperature 
of 62˚C. pcDNA3.1 vector and apoE4 fragment PCR product were subjected to 
restriction enzymes double-digestion with HindIII and BamHI. Samples were incubated 
with CIP to remove 5’ phosphate group and loaded onto 1% agarose gel for gel 
electrophoresis. (B) Correct DNA bands were excised carefully from the agarose gel 
under UV light. Excised gels were solubilized and subjected to QIAquick Gel Extraction 
Kit to obtain DNA fragments. After extraction, purified DNA fragments were subjected 
to gel electrophoresis for validation. (C)  Purified pcDNA3.1 vector and apoE4 fragment 
were ligated at room temperature for 4 hours before transformed into DH5α bacterial 
strains. Ten colonies were selected and subjected to miniprep. Extracted plasmids were 
digested with HindIII and BamHI, followed by gel electrophoresis for verification.  
 
5.3.2  Overexpression of apoE4 and apoE4 fragment perturbs mitochondrial 
dynamics 
ApoE4 has been reported to exert a detrimental effect on mitochondrial 
metabolism [196-198] and mitochondrial function [77].  Mitochondrial function is 
regulated and reflected by its dynamics. In addition, mitochondrial morphology 
and dynamics are also found to be impaired in the brains of AD patients [106,107]. 
Therefore, we examined whether apoE4 would affect mitochondrial dynamics. As 
shown in Figure 5-2A, the levels of mitochondrial fission proteins Drp1 and Fis1 
were increased, while the expression of mitochondrial fusion protein Mfn2 was 
repressed in cells overexpressed with apoE4 compared to control cells transfected 
with empty vector. To analyze mitochondrial morphology, cells were stained with 
MitoTracker Red CMXRos and visualized under confocal microscope. Figure 5-
2B showed that swollen mitochondria with short tubules were observed in cells 
overexpressing apoE4 and apoE4 fragment, suggesting an imbalance in 
mitochondrial fusion and fission. Statistical analysis of FF values that determine 
the interconnectivity of the mitochondria and AR values that measure the length 
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of the mitochondria from three independent experiments was performed. Results 
showed that cells overexpressed with apoE4 and apoE4 fragment have 
significantly lower FF values (mean ± S.E.M, n=10) and AR values (mean ± 

















































Figure 5-3. ApoE4 and apoE4 fragment induce abnormalities in mitochondrial 
dynamics. (A) SH-SY5Y cells were transfected with pCMV.–apoE4 or pCMV. vector. 
Samples were solubilized with Western blotting lysis buffer and probed with specific 
antibodies, addressing the protein levels of mitochondrial fission proteins Drp1, Fis1 and 
fusion proteins Mfn1, Mfn2, OPA1. (B) SH-SY5Y cells were transfected with human 
apoE4 or apoE4 fragment expression plasmids. Twenty four hours after transfection, cells 
were stained with MitoTracker Red CMXRos, fixed in paraformaldehyde and 
permeabilized in TritonX-100.  ApoE4 and apoE4 fragment proteins were probed with 
apoE primary antibody and detected by Alexa Fluor 488 anti-mouse IgG. Fluorescent 
signals were visualized under confocal microscope. (C) Mitochondrial morphology was 
determined by FF and AR using Image J software shape distributor plugin. The data 
represented average (n=10) ± S.E.M. and statistical significance was assessed with 
Student’s t test (*p<0.05, **p<0.01, ***p<0.001). 
 
5.3.3  ApoE4 and apoE4 fragment interact with LRP5/6  
In the previous chapter, we have demonstrated the interaction between apoE4 and 
LRP5/6 in both HEK293T and SH-SY5Y cells. Here, we explored the interaction 
further with apoE4 fragment. As shown in co-immunoprecipitation assay with 
HEK293T cells (Figure 5-3A), we were able to detect LRP5 and LRP6 in the 
protein complexes pulled down by apoE antibody, which confirmed the 
interaction between apoE4 and LRP5/6 shown in the last chapter. In addition, it 
also demonstrated an interaction between LRP5/6 and apoE4 fragment. 
Furthermore, LRP5/6 and apoE4 were transiently co-transfected in human 
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neuroblastoma cells SH-SY5Y. Similarly, LRP5 and LRP6 were detected in the 
protein complex immunoprecipitated by apoE antibody in SH-SY5Y cells (Figure 
5-3B). Next, we performed confocal microscopy to determine whether apoE4 
colocalized with LRP5/6. SH-SY5Y cells were transfected with LRP5/6 and 
apoE4 or respective vectors and probed with fluorescence-conjugated antibodies. 
The overlay image showed a colocalization between apoE4 (in red) and LRP5/6 
(in green) (Fig. 5-3C). PCC values that quantify the degree of colocalization 
between fluorophores were calculated using Fluoview Fv10-ASW. For cells 
overexpressing apoE4 and LRP5, PCC value was determined to be 0.944 ± 0.006 
(Table 5-3), suggesting a strong colocalization of the two proteins; similarly, a 
very strong colocalization were seen between apoE4 and LRP6 with PCC values 














Figure 5-4. Detection of the interaction between apoE4/apoE4 fragment and LRP5/6. 
(A) HEK293T cells were overexpressed with human wild-type apoE4 or apoE4 fragment 
together with LRP5 or 6 plasmids. Equivalent lysates were immunoprecipitated with 
apoE antibody, followed by immunoblotting with LRP5 or 6 antibodies (upper panels). 
Total lysates were probed for the indicated proteins (bottom panel). (B) SH-SY5Y cells 
were overexpressed with human wild-type apoE4 and LRP5/6 plasmids. The lysate was 
subjected to co-IP and Western blotting assays as described above.  (C) SH-SY5Y cells 
were overexpressed with apoE4 and LRP5/6, and fixed with paraformaldehyde followed 
by permeabilization using TritonX-100. The samples were then probed with specific 
primary antibodies for apoE and LRP5/6, followed by secondary antibodies Alexa Fluor 
568 goat anti-mouse IgG (recognizing apoE) and Alexa Fluor 488 goat anti-rabbit IgG 
(recognizing LRP5/6). The colocalization was measured by PCC using Fluoview Fv10-










Table 5-3 Statistical analysis of the degree of colocalization between apoE4 
and LRP5. 
Experimental Group PCC (Mean ± S.E.M.) 
CTL 0.743 ± 0.020 
LRP5 0.727 ± 0.020 
apoE4 0.849 ± 0.010 
apoE4 + LRP5 0.944 ± 0.006 
 
Table 5-4 Statistical analysis of the degree of colocalization between apoE4 
and LRP6. 
Experimental Group PCC (Mean ± S.E.M.) 
CTL 0.750 ± 0.015 
LRP6 0.295 ± 0.020 
apoE4 0.772 ± 0.041 
apoE4 + LRP6 0.958 ± 0.025 
 
5.3.4  DKK1 disrupts the interaction between apoE4 and LRP5/6 in a dose-
dependent manner 
DKK1 is a secreted protein that antagonizes Wnt/beta-catenin signaling by 
inhibiting LRP5/6 [199]. The ectodomain of LRP5/6 contains four β-
propeller/EGF-like domain repeats [127,200]. The binding of LRP6 to its ligand 
Wnt9b requires the first two repeats of β-propeller/EGF-like domain and the last 
two repeats are required for Wnt3a binding [201]. A crystal structural study 
showed that DKK1 C-terminal domain binds to the last two repeats and DKK1 N-
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terminal domain binds to the first two repeats of LRP6, demonstrating that DKK1 
can inhibit both receptor binding domains [202]. Therefore, we postulated that 
DKK1 might inhibit the interaction between apoE4 and LRP5/6. We 
overexpressed apoE4 and LRP5/6 in HEK293T cells, followed by treatment of 0, 
20, 50, 100ng/mL DKK1 for 24 hours. Co-immunoprecipitation assay showed 
that DKK1 dissociated the interaction in a dose-dependent manner (Figure 5-4A). 
As DKK1 significantly dissociates the interaction at a concentration of 100ng/mL, 
we subsequently used this concentration of DKK1 to treat SH-SY5Y cells. An 
obvious disturbance of the interaction was observed in SH-SY5Y cells treated 
with 100ng/mL DKK1 for 24 hours (Figure 5-4B). Confocal fluorescence 
microscopy analysis was performed to verify the changes in the colocalization of 
apoE4 and LRP5/6 (Figure 5-4C). With the treatment of DKK1, PPC values were 
significantly decreased from 0.944 ± 0.006 to 0.830 ± 0.015 for apoE4 and LRP5 
(Table 5-5); and reduced from 0.958 ± 0.025 to 0.817 ± 0.075 for apoE4 and 











































































































      
























Figure 5-5. DKK1 disrupts the interaction between apoE4 and LRP5/6 in both 
HEK293T cells and SH-SY5Y cells. (A) HEK293T cells were overexpressed with 
apoE4 and LRP5/6 plasmids, followed by treatment with 0, 20, 50, 100ng/mL DKK1 for 
24 hours. Equivalent lysates were immunoprecipitated with apoE antibody, followed by 
immunoblotting with LRP5 or 6 antibodies (upper panels). Total lysates were probed for 
the indicated proteins (bottom panel).  (B) SH-SY5Y cells were co-transfected with 
apoE4 and LRP5/6 expression plasmids before treatment with 0 and 100ng/mL DKK1 for 
24 hours. The lysate was subjected to co-IP and Western blotting assays as described 
above. (C) SH-SY5Y cells were overexpressed with apoE4 and LRP5/6, followed by 
treatment with 0 and 100ng/mL DKK1 for 24 hours before being harvested. Cells were 
fixed with paraformaldehyde and permeabilized using TritonX-100. The samples were 
then probed with specific primary antibodies for apoE and LRP5/6, followed by 
secondary antibodies Alexa Fluor 568 goat anti-mouse IgG (recognizing apoE) and Alexa 
Fluor 488 goat anti-rabbit IgG (recognizing LRP5/6). (D) The degree of colocalization 
was determined by PCC values calculated using Fluoview Fv10-ASW. Data was 
presented as the average (n=10) ± S.E.M. and statistical significance was assessed with 
Student’s t test (*p<0.05, **p<0.01, ***p<0.001). 
 
5.3.5  Dissociation of apoE4 and LRP5/6 restores perturbed mitochondrial 
dynamics  
To understand the mechanism underlying apoE4-induced abnormalities in 
mitochondrial dynamics, we analyzed the mitochondrial fusion and fission protein 
levels in apoE4 and LRP5/6 co-expressed SH-SY5Y cells treated with DKK1. As 
shown in Figure 5-5A, we found a reduction in the elevated mitochondrial fission 
proteins Drp1 and Fis1 levels and an increase in the repressed mitochondrial 
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fusion protein Mfn2. Under the confocal microscopy, collapsed and fragmented 
mitochondria around the nucleus were seen in cells overexpressed with apoE4 and 
LRP5/6, whereas mitochondria in the SH-SY5Y cells treated with DKK1 
remained filamentous and distributed across the cells (Figure 5-5B). FF and AR 
values showed that cells overexpressing apoE4 and LRP5/6 under the treatment of 
DKK1 have higher FF values (mean ± S.E.M, n=10) and AR values (mean ± 
S.E.M, n=10) as compared to cells without DKK1 treatment (Figure 5-5C).  
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Figure 5-6. Dissociation of apoE4 and LRP5/6 restores perturbed mitochondrial 
dynamics back to normal. SH-SY5Y cells were co-transfected with apoE4 and LRP5/6 
plasmids and treated with 0, 100ng/mL DKK1 for 24 hours. (A) Cell lysates were 
subjected to Western blotting assay, probing with specific antibodies for Drp1, Fis1, 
Mfn2, apoE, LRP5/6 and β-actin. (B) Cells were stained with MitoTracker Red CMXRos 
for 10 min before fixation with paraformaldehyde and permeabilization by TritonX-100. 
Samples were then probed with specific antibodies for apoE and LRP5/6, followed by 
secondary antibodies Alexa Fluor 488 goat anti-mouse IgG (recognizing apoE) and 
Chromeo™ 642 goat anti-rabbit IgG (recognizing LRP5/6). (C) AR values and FF values 
were calculated using Image J software shape distributor plugin to determine 
mitochondrial morphology. Data represented the average (n=10) ± S.E.M. and statistical 




5.3.6  Knockdown of LRP5/6 abolishes apoE4-induced disruption in 
mitochondrial dynamics  
To confirm the functional role of LRP5/6 in apoE4-induced abnormalities in 
mitochondrial dynamics, we performed gene knockdown experiments using 
siRNA on apoE4 overexpressing SH-SY5Y cells. Confocal microscopy was 
performed to examine mitochondrial morphology. As expected, SH-SY5Y cells 
overexpressed with apoE4 possessed swollen and fragmented mitochondria 
clumped around nuclei. To eliminate the possibility that DKK1 itself affects 
mitochondrial morphology, we treated apoE4 overexpressing SH-SY5Y cells with 
100ng/mL DKK1. As seen in Figure 5-6A, the morphology of mitochondria in 
cells overexpressing apoE4 under the treatment of DKK1 was similar to that of 
apoE4 transfected SH-SY5Y cells without DKK1 treatment, suggesting DKK1 
did not affect mitochondrial dynamics. Silencing of LRP5 and LRP6, however, 
were able to elongate mitochondrial units and distribute mitochondria across the 
whole cells. Statistical analysis of FF and AR values showed that depletion of 
LRP5 and LRP6 in the cells overexpressed with apoE4 lowered FF (mean ± 
S.E.M., n=10) and AR (mean ± S.E.M, n=10) as compared to cells without 
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Figure 5-7. Knockdown of LRP5/6 abolishes apoE4-induced disruption in 
mitochondrial dynamics. (A) SH-SY5Y cells were co-transfected with apoE4 plasmid 
and LRP5/6 siRNA before stained with MitoTracker Red CMXRos. Cells overexpressed 
with empty vector, apoE4 alone or apoE4 followed by treatment of DKK1 were used as 
control groups. Samples were fixed with paraformaldehyde and permeabilized by 
TritonX-100. Cells were then probed with anti-apoE antibody and detected with Alexa 
Fluor 488 goat anti-mouse IgG. (B) AR values and FF values were calculated using 
Image J software shape distributor plugin to determine mitochondrial morphology. Data 
was presented as the average (n=10) ± S.E.M. and statistical significance was assessed 
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5.3.7  Overexpression of apoE4 does not affect mitochondrial 
transmembrane potential 
In addition to mitochondrial morphology and size, mitochondrial dynamics also 
regulates mitochondrial functions. Studies have shown that the activities of 
mitochondrial complexes III and IV were affected in apoE4-induced toxicity [81]. 
Since complex III and IV are related to the maintenance of mitochondrial 
transmembrane potential, we examined the effect of apoE4 on mitochondria 
transmembrane potential. SH-SY5Y cells were transfected with apoE4 plasmids, 
followed by staining with JC-1 fluorescence dye, an indicator of mitochondrial 
transmembrane potential (ΔΨm). The green JC-1 monomers selectively enter into 
mitochondria and reversibly form aggregates with intense red fluorescence in the 
healthy cells with high ΔΨm. As expected, the treatment of STS induced a 
significant decrease in mitochondrial potential. On the other hand, there were no 
significance differences in JC-1 ratio (aggregates over monomers) when apoE4 
was overexpressed (Figure 5-7A). To determine if the interaction between apoE4 
and LRP5/6 could possibly affect mitochondrial transmembrane potential, we co-
transfected apoE4 and LRP5/6 in SH-SY5Y cells, followed by the treatment of 
DKK1 to dissociate the interaction. As shown in Figure 5-7B, no significant 
changes in ΔΨm were observed among the treatment groups except for the 
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Figure 5-8. Overexpression of apoE4 does not affect mitochondrial transmembrane 
potential. (A) SH5Y cells were overexpressed with human wild type apoE4 plasmids or 
pCMV.vector, followed by incubation with JC-1 mitochondrial transmembrane potential 
dye. JC-1 ratio was obtained by dividing JC-1 aggregate fluorescence by monomer 
fluorescence. The treatment of 250nM STS for 8 hours was used as a positive control to 
indicate the decrease in JC-1 ratio. (B) SH-SY5Y cells were transfected with designated 
expression plasmids before incubation with JC-1 fluorescence dye. Data represented the 
average (n=10) ± S.E.M. and statistical significance was assessed with one-way ANOVA 
with Dunnett’s post-hoc analysis (*p<0.05, **p<0.01, ***p<0.001). 
 
5.4  Discussion 
This study shows for the first time that apoE4 increases the levels of 
mitochondrial fission proteins Drp1 and Fis1 and decreases the level of 
mitochondrial fusion protein Mfn2. A subsequent elongated morphology of 
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mitochondria was observed, indicating unbalanced mitochondrial fusion and 
fission. We also report for the first time that apoE4 and its fragment bound to 
LRP5 and LRP6 in vitro. The interaction between apoE4 and LRP5/6 was 
disrupted by LRP5/6 inhibitor DKK1 in a dose-dependent manner. Furthermore, 
dissociation of apoE4 and LRP5/6 by DKK1 reduced the elevated Drp1 and Fis1 
protein levels and increased the repressed protein level of Mfn2, leading to 
restoration of normal mitochondrial dynamics. However, neither apoE4 nor the 
interaction/dissociation between apoE4 and LRP5/6 affected mitochondrial 
transmembrane potential. Taken together, LRP5/6 acts as a receptor for apoE4 in 
causing abnormalities of mitochondrial fusion and fission.  
 
Our findings suggest that apoE4 exerts its detrimental effect at least in part 
through perturbing mitochondrial dynamics. ApoE4 has been reported to induce 
mitochondrial dysfunction in AD patients [77]. Differential mitochondrial protein 
levels were seen in hippocampal tissue of apoE3 and apoE4 transgenic mice [84] 
as well as in apoE ε4 carriers and non-carriers [85]. However, no previous studies 
have implicated the role of apoE4 in mitochondrial fusion and fission, despite 
multiple lines of evidence indicating the mitochondrial dynamics to be perturbed 
in AD. Morphometric analysis revealed that mitochondria not only decreased in 
number but also enlarged in size in AD neurons [78]. The finding of enlarged and 
swollen mitochondria was also observed in AD cybrid cells [92] and fibroblasts 
from LOAD patients [106]. However, there are some discrepancies in the analysis 
of mitochondrial dynamics-related protein levels. Wang et al. reported a 
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significantly decreased level of Drp1 in 19.3% of sporadic AD fibroblasts along 
with elongated mitochondria accumulation in the perinuclear area [93]. The group 
also showed that an overexpression of wild-type Drp1 in the fibroblasts rescued 
mitochondrial abnormalities [93]. Moreover, studies with detailed immunoblot 
analysis indicated that the levels of Drp1, OPA1, Mfn1 and Mfn2 were 
significantly decreased whereas the level of Fis1 was increased in AD brain [107]. 
In contrast to the above reported studies, Manczak et al. showed an increased 
expression of Drp1 and a reduction in that of Mfn1 and Mfn2 in AD patients 
[203]. Our results reported that apoE4 increased the protein levels of Drp1 and 
Fis1 and decreased that of Mfn2, which corresponds to the observation in AD 
subjects made by Manczak et al.  However, the link between apoE4 and 
mitochondrial dynamics-related protein levels has still yet to be verified with 
further studies using primary neurons and in vivo models. Although the 
mitochondrial protein levels have been analyzed, there are still some 
discrepancies regarding the effect of apoE4 on mitochondrial integrity. Chang et 
al. reported that mitochondrial potential and integrity was impaired by apoE4 
through the lipid- and receptor-binding regions [80]. However, the studies by 
Nakamura et al. showed that overexpression of apoE4 had no effects on ΔΨm 
[81]. Supporting the observation in the latter study, our results showed that the 
presence of apoE4 did not affect ΔΨm. Whether other mitochondrial functions are 
affected as a result of abnormal mitochondrial dynamics induced by apoE4, will 




Although we have identified apoE4-mediated changes in the mitochondrial 
morphology and disruptions in mitochondrial dynamics related protein levels, the 
mechanism underlying these abnormalities remains unclear. One possible 
pathway may be through binding to its receptors, members of LDL receptor 
family. Up till now, only two members of the family, LRP1 and LRP6, have been 
reported to genetically associate with AD. The polymorphism of LRP1 is a minor 
risk factor for AD [169,204], whereas LRP6 polymorphism Val1062 has been 
reported to act synergistically with apoE4 ε4 allele [140]. Our study confirmed the 
direct interaction between apoE4 and LRP5/6 at the protein levels. Using DKK1 
as an inhibitor to dissociate the binding, we were able to restore the disrupted 
levels of mitochondrial dynamics-related proteins and altered mitochondrial 
morphology back to normal. However, neither the interaction nor the dissociation 
between apoE4 and LRP5/6 showed any significant effects on mitochondrial 
transmembrane potential. Taken together, our study shows that apoE4 
dysregulates mitochondrial fusion and fission processes via binding to LRP5 and 
LRP6.   
 
 
5.5  Conclusion 
To summarize, results in this chapter showed for the first time that apoE4 carries 
out its detrimental effect in neuronal cells through disrupting mitochondrial 
dynamics and this process is regulated by LRP5/6. With the increasingly 
important role of mitochondria in neurobiology and AD physiopathology, 
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dissociating the interaction between apoE4 and LRP5/6 could be explored as the 
potential therapeutic strategy for inhibiting apoE4-induced pathology in AD.   
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CHAPTER 6. CONCLUSION AND FUTURE PERSPECTIVES 
 
The overall goal of this thesis was to understand the functional role of LRP5 and 
LRP6 in the pathology and etiology of AD. To achieve the overall goal, we 
proposed two hypotheses to investigate the potential implication of these two 
proteins in the mechanism of AD with neuronal cell lines. 
 
In Chapter 3, we addressed the first hypothesis wherein we reported that 
overexpression of LRP5 and LRP6 has a neuroprotective role in improving cell 
survival and reducing tau phosphorylation in neuronal cells. In Aim 1, we showed 
that overexpression of LRP5 and LRP6 upregulated Wnt activity. As a result, 
mRNA levels of proliferative markers Axin2 and Cyclin D1 were significantly 
increased with LRP5 and LRP6 overexpression in SH-SY5Y cells treated with 
Wnt3a ligands. In contrast, Wnt activity was significantly decreased in LRP5- and 
6- knockdown cells respectively. For the transcription of downstream survival 
genes Axin2 and Cyclin D1, mRNA levels were significantly downregulated with 
LRP5 and LRP6 repression. Moreover in Aim 2, we reported that LRP5 and 
LRP6 overexpression were able to ameliorate hydrogen peroxide-mediated 
cytotoxicity at all concentrations used.  The protective role of LRP5 and LRP6 
was further confirmed by reduced Sub G0/G1 apoptotic population. We also 
observed decreased levels of cleaved caspase 3 and 7 in the LRP5- and 6- 
overexpressed cells. Lastly in Aim 3, LRP5 and LRP6 overexpression reduced 
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GSK3β activity and decreased phosphorylated tau protein. Thus, we have 
successfully proven our hypothesis that overexpression of LRP5 and LRP6 
protects neuronal cell from cytotoxicity induced by hydrogen peroxide and 
reduces tau phosphorylation in SH-SY5Y cells. 
 
The present work has raised several issues to be pursued in future investigations. 
We demonstrated that overexpression of LRP5 and LRP6 protected SH-SY5Y 
cells from oxidative stress-induced cell death. Although implicated in the 
pathogenesis of AD, oxidative stress has been suggested to result from Aβ 
aggregation. The accumulation of Aβ in the brain has been widely accepted to be 
one of the possible causes for neurodegeneration in AD. In the present study, the 
attempt to establish AD cell model with Aβ challenge was not successful with no 
significant cell death. Despite hydrogen peroxide was used as an alternative, Aβ 
challenge provides a more suitable AD model. Therefore, one future direction 
could be to optimize and establish Aβ-challenged AD model. In addition, given 
that the Wnt signaling pathway is involved in normal cell growth, continuous 
activation of this signaling pathway may result in excessive neuronal stimulation, 
probably leading to tumorigenesis. Thus, it would be a potential challenge to 
ensure the selectivity of therapeutic strategies against pathological cells 
specifically to avoid tumorigenic side effects of overstimulating Wnt pathway. 
The findings in Chapter 3 suggested that modulating Wnt signaling through 
overexpression of LRP5 and LRP6 is a promising approach for AD therapy. 
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However, this hypothesis has only been proven in human neuroblastoma SH-
SY5Y cells. Future studies with a wider range of neuroblastoma cell lines, 
primary neurons harvested from transgenic mice and AD patient cell samples are 
required to confirm and supplement our findings to better clarify the potential of 
LRP5 and LRP6 as therapeutic targets. Furthermore, despite our in vitro 
experiments showed some encouraging results, the in vivo efficacy of this 
approach needs to be confirmed in AD transgenic mouse models. 
 
In Chapter 4 and 5 (discussing the second hypothesis), we evaluated the 
interactions of apoE isoforms with LRP5/6 and apoE4-mediated abnormalities in 
mitochondrial dynamics. In Aim 1, we detected the presence of LRP5 and LRP6 
in the protein complex pulled down by apoE antibody, which indicated the 
interaction between LRP5/6 and apoE4 in both HEK293T and SH-SY5Y cells. 
Moreover, the interaction between apoE isoforms and LRP5 abolished the 
activation ability of LRP5 and exerted isoform-specific effects on GSK3β activity. 
In Aim 2, our results indicated that overexpression of apoE4 increased the protein 
levels of mitochondrial fission proteins Drp1 and Fis1 and reduced that of 
mitochondrial fusion protein Mfn2 compared to SH-SY5Y cells overexpressing 
empty vector. Under the confocal microscope, cells overexpressing apoE4 were 
observed to present short tubules and clumps of tangled mitochondria surrounding 
the nucleus, in contrast to the normal mitochondria with a combination of short 
and long filament-like structures distributed throughout the cell. The presence of 
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clumps and fragmented mitochondria indicated an imbalance in mitochondrial 
fusion and fission. Furthermore in Aim 3, we identified that the Wnt antagonist 
DKK1 dissociated the binding between apoE4 and the two receptors in a dose-
dependent manner. With the treatment of DKK1, we observed that the disrupted 
mitochondrial morphology was restored back to filamentous structures distributed 
across the cells and the degree of mitochondrial clustering was less intense as 
compared to those without treatment. Hence, our results have proven that apoE4 
alters mitochondrial dynamics through binding to LRP5/6. 
 
In Chapter 4, we only showed the binding of apoE isoforms and their effects on 
Wnt signaling as well as GSK3β activity, with LRP5 in neuronal cells. The 
binding ability of LRP6 and the effects on Wnt signaling needs to be evaluated 
with further studies. In addition, Cedazo-Minguez et al. reported that the effect of 
apoE3 and apoE4 on GSK3β activity is time-dependent [173]. Thus, the effect of 
interaction between apoE isoforms and LRP5/6 in regulating GSK3β activity and 
tau phosphorylation should be evaluated at different time points.  The present 
study focused on evaluating the effect of apoE isoforms on Wnt activity or 
GSK3β by transfecting cells with expression plasmids encoding for the three 
isotypes. Since apoE proteins are mainly secreted by astrocytes and target the 
receptors on neurons in the physiological condition, a more relevant model of 
future studies on the mechanism would be to treat neuronal cells with medium 
collected from astrocyte transfecting with apoE isoforms.  In Chapter 5, our 
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findings indicated that apoE4 caused the imbalance in mitochondrial fusion and 
fission processes through binding to LRP5 and LRP6. However, the effect of the 
interaction between other apoE isoforms and LRP5/6 on mitochondrial dynamics 
still remains unclear. Questions such as whether apoE2/3 carries out beneficial 
effects in maintaining mitochondrial dynamics and the role of the interaction 
between apoE2/3 and LRP5/6 on this beneficial effect should be addressed in 
order to have a better understanding of the differential effects of apoE isoforms in 
AD. In addition, in this chapter we reported that dissociation of apoE4 and 
LRP5/6 with LRP5/6 antagonist DKK1 restores the disturbance in mitochondrial 
dynamics. Another approach to disrupt the interaction is to identify an apoE4 
antagonist to free up apoE4 bound LRP5/6, abolishing the detrimental effect on 
mitochondrial dynamics. Moreover, despite aberrantly regulated mitochondrial 
functions being repeatedly associated with AD in neuronal cells as well as AD 
patient samples [81,83], the underlying mechanism has not been fully understood. 
Our preliminary results failed to show that the interaction between apoE4 and 
LRP5/6 had any significant effect on mitochondrial transmembrane potential. 
This may possibly be due to the lack of optimization in transfection and treatment 
duration or because this interaction is involved in the early stage of mitochondrial 
dysfunction. Thus, an optimized study needs to be conducted to assess the effect 
of this interaction on mitochondria integrity. Lastly, the unique conformation of 
apoE4 makes it more susceptible to misfolding and instability, resulting in 
proteolysis and the generation of neurotoxic apoE fragment to a greater extent 
than other apoE isoforms, which has been reported to be involved in 
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mitochondrial dysfunction, cytoskeletal alterations and neuronal cell death [80,81]. 
Our results showed that apoE4 fragment also bound to LRP5/6. However, the 
involvement of apoE4 fragment in the downstream detrimental effect on 
mitochondrial dynamics needs to be confirmed with the evaluation of 
mitochondrial dynamics related protein levels and mitochondrial morphology. 
Moreover, whether this interaction is involved in the internalization and cleavage 
of apoE4 into fragment requires further studies to quantify the fragment under the 
treatment of DKK1.  
 
The results from Chapter 5 might seem to be discrepant with the beneficial effect 
of LRP5/6 concluded from Chapter 3. However, in Chapter 3 the beneficial effect 
of LRP5 was observed in the presence of exogenous Wnt3a ligands, but not 
apoE4. In addition, the endogenous apoE levels were beyond limit of detection, 
suggesting the effect of endogenous apoE proteins are marginal compared with 
that of exogenous Wnt3a ligands. In Chapter 5, when both apoE4 and LRP5 were 
overexpressed, LRP5 was occupied by apoE4 with no presence of exogenous 
Wnt3a ligands. The beneficial effect of endogenous Wnt3a on LRP5 was masked 
by the detrimental effect of exogenous apoE4 on LRP5. Therefore, it is likely that 
LRP5 has a dual role, beneficial to neuronal cell survival with the presence of 




In conclusion, the findings of this thesis have not only helped in identifying the 
dual functional role of Wnt co-receptors LRP5 and LRP6 in AD, but have also 
indicated that LRP5 and LRP6 could be explored and developed as novel 
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